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Geriatric populations are at a higher risk for adverse drug reactions (ADRs). This may be 
partly due to changes in drug metabolism in old age, but the underlying mechanisms are poorly 
understood. Prior research in humans and mice has shown age-associated changes to the 
expression of several genes involved in drug metabolism. Furthermore, studies of human blood 
showed that epigenetic regulation of genes encoding drug metabolizing enzymes change with 
age. However, it is unknown if genes in the liver are similarly affected. Therefore, we 
hypothesize that genes encoding drug metabolizing enzymes may show differential epigenetic 
regulation in the liver with age, and that this will affect rates of drug metabolism. 
We selected genes encoding phase I and II drug metabolizing enzymes showing the 
strongest evidence of age-related epigenetic changes in prior genome-wide studies of human 
blood DNA. We mapped the homologues of these genes in mice and analyzed DNA methylation 
and histone acetylation levels in liver samples from aged mice (4, 18, 24 and 32 months) coupled 
with functional investigations at those genes. We successfully demonstrated a strong relationship 
between DNA methylation and histone acetylation (H3K9ac) levels at cytochrome P450 2E1 
xiii 
 
(Cyp2e1) and sulfotransferase family 1A member 1 (Sult1a1) and their expression levels in liver. 
Moreover, intrinsic clearance of the CYP2E1 probe drug chlorzoxazone was strongly associated 
with DNA methylation and histone acetylation at two regulatory regions of Cyp2e1. Next, we 
investigated DNA methylation levels at these genes in peripheral blood and organs like the liver 
and the brain. We show that DNA methylation levels of Cyp2e1 and Sult1a1 are substantially 
different between blood, liver, and the brain and are correlated to various extents and directions 
of effects. Finally, we report an optimized method for genome-wide investigation, Reduced 
Representation Bisulfite Sequencing (RRBS), of methylation levels using the innovative 
Adaptase technology for utilization in larger aging studies of epigenetics and drug metabolism 
by our group in the future. Our successful demonstration of epigenetic control of drug 
metabolism in an aged mouse model could pave the way for future clinical studies to develop 





Chapter 1: The role of epigenomics in personalized medicine: a literature review 
The majority of this chapter was published in 
Kronfol MM, Dozmorov MG, Huang R, Slattum PW, McClay JL. The role of epigenomics in personalized 
medicine. Expert Rev Precis Med Drug Dev. 2017;2(1):33–45. doi:10.1080/23808993.2017.1284557 
Additional excerpts taken from 
Kronfol MM, McClay JL (2019) Chapter 14 - Epigenetic biomarkers in personalized medicine. In: Sharma S (ed) 
Prognostic Epigenetics. Academic Press, pp 375–395 
 
1.1. Introduction 
Personalized medicine is founded upon the concept that individual differences in therapeutic 
success are the norm among patients that require pharmacological treatment. This concept is not 
new. Hippocrates writing in the 5th century BCE is known to have commented, “give different 
ones [drugs] to different patients, for the sweet ones do not benefit everyone, nor do the 
astringent ones, nor are all the patients able to drink the same things.” (see Sykiotis et al. 2005). 
Thus, the concept of variable response to drugs has been discussed for at least two and a half 
millennia. However, being able to predict who will respond to a given drug has proven an 
enduring challenge. With the advent of modern genomic technologies, which enable us to read 
each patient’s genetic make-up, the idea of personalized medicine is becoming a reality. 
Pharmacogenetics, the core discipline of personalized medicine, has already delivered some 
profound and meaningful successes. The effectiveness of Cytochrome P450 (CYP450) 
genotypes in predicting an individual’s drug metabolizing phenotype is a notable example 
(Ingelman-Sundberg 2004a). This has led to several of these biomarkers being approved for 
clinical use by regulatory bodies such as the US Food and Drug Administration (FDA) 
(www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm). 
Beyond drug metabolism, genetic variants at numerous other loci have shown robust associations 
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indicative of clinical relevance, with commercial kits and services now available to deliver this 
information to health providers and consumers (McCarthy et al. 2013). 
In the last decade, pharmacogenetics has harnessed the power of genome-wide association 
studies (GWAS). This has enabled the field to move beyond the study of candidate genes to 
scanning hundreds of thousands of genetic markers for each subject. Several promising new 
leads have been discovered. Arguably, however, the success of GWAS in pharmacogenomics 
has not mirrored that of complex disease studies. Primarily this may be an issue of statistical 
power, whereby the clinical trials necessary to measure drug response are costly and so sample 
sizes currently tend to be small. As studies grow in size and number and meta-analyses are 
conducted across samples, we can expect GWAS to yield additional insight over time (Ritchie 
2012). However, GWAS will not yield all the answers for any given drug response phenotype. 
Beyond the limitation where GWAS focuses on common polymorphisms, even if all the relevant 
variants for response to a given drug were mapped, we would still be unable to explain all the 
phenotypic variation in drug response (Manolio et al. 2009). Drug response is complex and, like 
other complex traits, it likely arises from the interplay of multiple genetic and environmental 
factors over the life course (Cardon and Harris 2016). DNA sequence is just one component of 
this complexity. 
Most genotype associations in complex traits such as drug response are probabilistic 
indicators of phenotype, which typically say little of certainty about the state of the organism at 
the time of sampling. When treating an individual patient with a specific drug, substantial 
supporting information in addition to genotype information may be required before making a 
clinical decision. Even phenotypes that are strongly influenced by genetics, such as the CYP450 
drug metabolism phenotypes, will be modified by the effects of concurrent medications or 
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alcohol and tobacco use that may inhibit or interfere with CYP enzyme activity (He et al. 2015; 
Tracy et al. 2016). This further illustrates the need to consider information beyond genotype 
alone. 
There are two broad complexities to living organisms that are not addressed by genotype 
information. These are 1) spatial and 2) temporal variation in biological function or phenotypic 
expression within the same organism. Consider that humans are composed of multiple cell types 
with a diverse array of functions (spatial, or cell-specific variation) and that we take on very 
different macroscopic forms in early versus later life (temporal, or developmental variation). Yet 
essentially the same genome is present in all nucleated cells at all-time points. In this chapter, we 
will show how the processes that lead to cellular diversity and organismal development, i.e. 
epigenetics, can be harnessed to provide more nuanced DNA-based biomarkers and novel 
treatment strategies (Bock 2009). Indeed, epigenetics may also yield an environmental exposure 
record of the patient that we are just beginning to comprehend (Ladd-Acosta 2015). Epigenetic 
biomarkers are therefore fundamentally different to studies of gene expression, proteins or 
metabolites, which provide snapshots of functional state at a single time point. Epigenetics 
provides layers of regulatory and environmental exposure information on top of each 
individual’s unique genome (Feinberg 2007). Thus, it indicates what happened to you and you 
alone, and from this we may be able to determine your truly personal drug regimen design and 
success, disease susceptibility and cure. 
1.2. Epigenetics Overview 
The term “epigenetics” was first described by the British developmental biologist Conrad 
Waddington in the 1940s as “the branch of biology which studies the causal interactions between 
genes and their products, which bring the phenotype into being” (Goldberg et al. 2007; Noble 
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2015). Waddington’s definition therefore predates the discovery of DNA and so the term 
“epigenetics” has developed over time. Waddington was focused on organismal development, 
whereby cells starting with the fertilized egg follow trajectories of increasing specialization until 
terminal differentiation, which cannot be reversed. One of Waddington’s visual metaphors for 
this process, where the cell is conceptualized as a marble rolling down a rolling hillside with 




Figure 1.1. Waddington represented the developmental process as a series of “decisions” made 
by differentiating cells that could be represented as forks in the valleys of the “developmental 
landscape”. Panels A and B represent the alternate fates of the cell, or ball by analogy. As the 
pluripotent stem cell of the egg (ball at the top), begins to specialize, the differentiation 
“decisions” made are irreversible. Its pattern of epigenetic regulation is established by the point 
of terminal differentiation at the bottom of the landscape. With epigenetic drugs and therapies, 
the aim is to artificially reverse maladaptive epigenetic states and essentially “push the ball back 




Today, backed by knowledge of the genome and some core molecular processes, epigenetics 
can be defined as the study of mitotically stable changes in genetic regulation that do not involve 
changes to nucleotide sequence (Russo et al. 1996). Mitotic stability, in this sense, means that the 
epigenetic state of the parent cell is written to the daughter cell after mitosis, thereby continuing 
the developmental trajectory of the parent. This regulation is enacted via epigenetic marks, 
which are reversible regulatory modifications to chromatin. 
1.2.1. Epigenetic modifications to chromatin 
The most intensively studied epigenetic mark is the methylation of DNA cytosine 
residues at the carbon 5 position (5mC). This mark is made via the DNA N-methyl transferase 
(DNMT) enzymes and is most often found in the sequence context CpG (Irizarry et al. 2009). 
DNA methylation is one of the core epigenetic marks essential for regulating gene expression in 
normal cell development and differentiation (Reik et al. 2001). While 5mC is the most well-
characterized, other cytosine modifications have now been discovered, such as 5-
hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et 
al. 2011; Bachman et al. 2015). The functions of these exotic marks are still being elucidated, but 
5hmC may play an important role in the central nervous system, where it is prevalent, and in the 
regulation of pluripotency in stem cells (Kriaucionis and Heintz 2009; Pastor et al. 2011). 
Another major class of epigenetic mark involves the post-translational modification of 
histones, the proteins that package DNA into nucleosomes (Jenuwein and Allis 2001). Histones 
are the chief protein components of chromatin, whereby 146 bp of DNA is wound around each 
histone octamer (Luger et al. 1997). There are five major classes of canonical histones, where 
each octamer is typically formed of two H2A-H2B dimers and a H3-H4 tetramer while H1 
serves as a linker protein between nucleosomes. H3 and H4 have long tails that protrude from the 
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nucleosome that can be covalently modified in several places, while other histones can also be 
modified to a lesser degree. The best characterized modifications include mono-, di- and tri-
methylation, acetylation and phosphorylation, although a growing number continue to be 
reported (Bannister and Kouzarides 2011). Standard nomenclature abbreviates the histone, the 
modified residue and the type of modification, such that histone 3 lysine 27 acetylation is written 
as “H3K27Ac”. These modifications are written and erased by specific enzyme families, such as 
histone acetyltransferases (HATs) and histone deacetylases (HDACs) in the case of acetylation 
marks, or histone methyl transferases (HMTs) and demethylases (HDMs) in the case of 
methylation marks (Bannister and Kouzarides 2011). 
In addition to histone modifications, histone variants can have significant transcriptional 
regulatory roles. Histone variants replace canonical histones to alter nucleosome structure and 
ultimately DNA accessibility (Weber and Henikoff 2014). An example histone variant is H2A.Z, 
which replaces nucleosomal H2A to perform several complex regulatory roles in gene expression 
and development (Marques et al. 2010). Finally, for the purposes of this chapter, we also 
mention polycomb epigenetic repressors and bromodomain-containing proteins. Polycomb 
proteins can remodel chromatin and typically function as epigenetic gene silencers (Entrevan et 
al. 2016), while bromodomain proteins are transducers of the acetylation signal on histones 
(Filippakopoulos and Knapp 2014). These chromatin-interacting proteins are relevant for 
epigenetic personalized medicine because they are targets for epigenetic drugs that we mention 
below in Section 1.3.2. Other putatively epigenetic regulatory mechanisms exist, most notably 
the non-coding RNAs (ncRNAs). NcRNAs primarily function as post-transcriptional regulators 
of gene expression, but also play roles in regulating chromatin accessibility. They have been 
extensively reviewed elsewhere (http://www.cell.com/cell/collections/noncoding-rna). 
7 
 
1.2.2. Epigenetic effects on gene expression and regulation 
The “textbook”, or classic, view of epigenetic regulation is focused on DNA methylation 
at gene promoters. In this view, hypomethylated CpGs are typically associated with active, 
expressed genes, while hypermethylated CpGs are typically associated with silenced genes. This 
effect arises because methylation of cytosine inhibits transcription factor binding (Jaenisch and 
Bird 2003). Subsequent research has indicated that methylated cytosine, in addition to 
methylated histone H3K9, and deacetylated H3 combine to form a repressive epigenetic 
signature, while unmethylated DNA, methylated H3K4, and acetylated H3 combine to form an 
activating epigenetic signature (Ivanov et al. 2014), although not all histone modifications are 
coupled with DNA methylation (Hansen and Helin 2009). An overview is provided in Figure 
1.2. During development, epigenetic patterns change and differentiated cells develop a stable and 
unique epigenetic pattern that regulates tissue-specific gene transcription. While this view is 
broadly consistent with current findings, waves of new genomic data have yielded a more 
nuanced view. 
Massive studies such as ENCODE (ENCODE Project Consortium 2012) and Roadmap 
Epigenomics (Roadmap Epigenomics Consortium et al. 2015) have significantly advanced our 
understanding of genetic and epigenetic regulation. The ENCODE project aims to identify all 
functional elements in the genome, while RoadMap Epigenomics aims to elucidate epigenetic 
processes that contribute to human biology and disease. Both projects make extensive use of 
next-generation sequencing (NGS) to profile reference epigenomes and genome-wide protein-
DNA binding patterns, including binding patterns for specific modified histones. The most recent 
culmination of these efforts was the publication of 111 reference epigenomes by RoadMap 
Epigenomics (Roadmap Epigenomics Consortium et al. 2015). This study revealed epigenetic 
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regulatory modules of coordinated activity, which are specific combinations of DNA 
methylation, histone modifications and other proteins that shape chromatin structure, which in 
turn determine transcriptional activity. These multi-layer data were used to classify genomic 
regions according to functional state (Ernst et al. 2011). The working models produced by 
RoadMap Epigenomics include a core 15 chromatin state model (Roadmap Epigenomics 
Consortium et al. 2015) and an expanded 18 chromatin state model 
(http://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html), the latter including twelve 
active and six inactive states. Active states include transcribed regions, active transcription start 
sites and their flanking regions, active enhancers and zinc finger protein binding sites. Inactive 
states include heterochromatin and repressed polycomb regions. This model, although complex, 
has already proven powerful for understanding regulation of gene expression.(Consortium 2015; 
Aguet et al. 2017) 
1.2.3. Individual differences in epigenetic states and developmental plasticity 
Epigenetic modifications to chromatin are affected by exposure to environmental factors, 
and any changes so induced are inherited mitotically in somatic cells (Feinberg 2007). Studies in 
human twins have shown that, while their epigenomes are very similar in early life, they diverge 
as the twins become older as a result of differing environmental exposures across the life course, 
in addition to stochastic effects (Fraga et al. 2005). Epigenetic changes in response to 
environmental factors may have evolved to provide plasticity in adaptation to environmental 
cues (Feinberg 2007). Through the phenomena of de novo epigenetic writing and mitotic 
stability, the effects of environmental factors can become embedded in the genome and persist to 
produce long-term phenotypic changes (Feil and Fraga 2012). Example environmental factors 
with demonstrated developmental consequences include diet, toxins and stress. There is 
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increasing recognition of the importance of this phenomenon for epigenetic translational 
research, because it provides concrete biological pathways that are involved in the persistence of 










Figure 1.2. Epigenetic regulation of gene expression via chromatin remodeling. The diagram 
shows two generic chromatin activity states. At the top, active chromatin is open and accessible 
to transcription factors and polymerases, with nucleosomes spread apart, DNA typically in an 
unmethylated state and acetylation marks on histones. HAT is histone acetyltransferase, 
SWI/SNF is a nucleosome remodeling complex, RNA Pol II is RNA polymerase II. The lower 
panel shows the opposite inactive chromatin scenario, where the nucleosomes are tightly packed, 
the DNA is methylated and inaccessible to transcription factors, while histones have their 
acetylation marks removed. HDAC is histone deacetylase, HMT is histone methyltransferase. 
Figure is adapted from Luong, P. Basic Principles of Genetics, Connexions Web site. 




Epigenetic states can also vary between individuals because of genetic differences. In the 
case of methylation, one of the simplest examples involves polymorphic CpG sites (Zhi et al. 
2013). If a nucleotide substitution ablates a CpG in some individuals, those individuals cannot be 
methylated at that locus. There are several examples of disease-associated polymorphic CpGs, 
suggesting that this is a significant contributor to individual differences in disease risk (Cazaly et 
al. 2015; Zhou et al. 2015). In addition to polymorphic CpGs, DNA sequence variation may also 
affect the binding of chromatin-interacting proteins and thus influence epigenetic states (McClay 
et al. 2015). Thus, individual differences in epigenetic states, whether arising via genotype or 
maladaptive responses to environmental factors, can lead to disease. 
1.3. Epigenetic Applications in Personalized Medicine 
Epigenetic disease associations provide not only mechanistic clues to disease etiology but 
can also function as diagnostic biomarkers. The developmental stage- and tissue-specificity of 
epigenetic marks has led to considerable interest in developing biomarkers that capitalize on 
these unique properties (García-Giménez 2015). Furthermore, the fact that epigenetic marks are 
reversible has led to significant interest in the development of drugs with epigenetic modes of 
action (Szyf 2009; Hunter 2015). 
1.3.1. Epigenetic biomarkers of disease 
The largest body of work in disease epigenetics to date is on cancer. Since the first links 
between DNA methylation and cancer were established in the early 1980s, a number of 
epigenetic findings have been described, implicating several aspects of the epigenetic machinery. 
Some excellent reviews of cancer epigenetics have been published recently (Suvà et al. 2013; 
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Feinberg et al. 2016), so here we limit ourselves to epigenetic marks in cancer showing evidence 
or potential as diagnostic or prognostic biomarkers. 
Current epigenetic biomarker applications predominantly involve DNA methylation 
(Amacher 2016). In the United States, nucleic acid-based tests intended for general clinical use 
are regulated by the Food and Drug Administration (FDA) as medical devices. Currently there 
are no FDA-approved tests that rely exclusively on epigenetic biomarkers. However, one 
commercially available test with an epigenetic component has received full FDA approval. This 
is ColoGuard®, a screening test for colorectal cancer in adults over 50. The test uses DNA 
methylation levels at BMP3 and NDRG4, in combination of mutated KRAS and an 
immunochemical assay for hemoglobin (Table 1.1). This test was reported to have superior 
sensitivity but slightly lower specificity for colorectal cancer compared to the traditional 
screening method, fecal immunochemical testing (FIT) (Imperiale et al. 2014). However, more 
recent results suggest FIT may be more effective and less costly than ColoGuard®, the latter 
necessitating either very high patient uptake or a 60% reduction in cost per test to become the 
preferred testing method (Ladabaum and Mannalithara 2016). This illustrates the economic 
barriers that diagnostic tests must overcome, beyond the demonstration of efficacy and 
reproducibility, in order to become widespread. 
Two other epigenetic tests are currently available in the US, classified as Laboratory 
Developed Tests (LDTs) and regulated under the Clinical Laboratory Improvement Amendments 
(CLIA) program. This means that the test may only be conducted “in house” in the laboratory 
where it was developed, once the lab meets CLIA performance standards. The two tests are 
ConfirmMDx and AssureMDx, for prostate cancer and bladder cancer respectively. 
Hypermethylation of the glutathione S-transferase gene (GSTP1) promoter in prostate cancer 
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was first shown in the 1990s (Lee et al. 1994). This marker, plus APC and RASSF1, are now 
components of the ConfirmMDx test (Table 1.1), which is used to address false-negative 
prostate biopsy concerns (Partin et al. 2014). The AssureMDx test for bladder cancer involves 
the analysis of DNA methylation levels of three genes (TWIST1, ONECUT2 and OTX1) in 
combination with mutation analysis of three others (van Kessel et al. 2016). 
In lung cancer, the DNA methylation of the SHOX2 gene was reported to be an accurate 
marker for identifying lung cancer based on analysis of bronchial aspirates (Schmidt et al. 2010). 
In Europe, this biomarker is now commercially available as the Epi proLungVR BL Reflex 
Assay (Dietrich et al. 2012). However, this test has not yet received regulatory approval for use 
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In breast and ovarian cancer, hypermethylation of the BRCA1 promoter region has been 
observed repeatedly (Cancer Genome Atlas Research Network 2011; Stefansson and Esteller 
2013). BRCA1 is also thought to epigenetically repress expression of the oncogenic microRNA 
miR-155 via a mechanism involving histone deacetylase 2 (HDAC2) (Chang et al. 2011). A 
recent study by Anjum et al. (2014) identified a blood cell DNA methylation signature at BRCA1 
that was able to predict breast cancer risk several years prior to diagnosis (Anjum et al. 2014). 
However, this biomarker is not yet available in a commercial kit or test. 
The biomarker potential of circulating cell-free DNA (cfDNA) has been investigated in 
breast cancer and other cancers. Circulating cfDNA is extracted from plasma or serum and is 
derived from dying tumor cells that release their DNA into the bloodstream. Kloten et al (2013) 
used a panel of three genes (ITIH5, DKK3 and RASSF1A) that showed hypermethylation in 
serum cfDNA from breast cancer patients and found these could discriminate between patients 
and controls with a sensitivity of 67% and specificity of 69% (Kloten et al. 2013). Fackler et al. 
(2014) followed this with a panel of 10 genes and cancer-specific DNA was detected in sera with 
a sensitivity of 91% and specificity of 96% in the test samples (Fackler et al. 2014). The 
researchers of the latter study are reportedly working with the diagnostics company Cepheid to 
bring this test to market (Butkus). 
While epigenetic studies of cancer are arguably the most advanced relative to other areas, 
several diseases have shown promising findings, particularly with respect to DNA methylation. 
These include neurological disorders such as Alzheimer’s Disease (De Jager et al. 2014; Lunnon 
et al. 2014) and Parkinson’s Disease (Jowaed et al. 2010), autoimmune disorders such as 
systemic lupus erythematosus (Absher et al. 2013), and psychiatric disorders such as 
schizophrenia (Pidsley et al. 2014; Aberg et al. 2014) and autism (Ladd-Acosta 2015). Despite 
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these advances, there are no currently available diagnostic kits for these diseases that employ 
epigenetic markers. Nevertheless, it is hoped that the clinical value of epigenomics already seen 
in oncology will be replicated in these areas (Heyn and Esteller 2012). 
1.3.2. Epigenetic drugs 
The dynamic and reversible nature of epigenetic modifications is of particular relevance 
to drug development, as it implies that specific disease-associated epigenetic states may be 
reversible with pharmacological treatment (DeWoskin and Million 2013). This segment will 
summarize current and potential “epidrugs”, or drugs with epigenetic modes of action. Epidrugs 
are classified according to their respective target enzymes, and include the following: DNA N-
methyl transferase inhibitors (DNMTi), histone acetyltransferase inhibitors (HATi/KATi), 
histone methyltransferase inhibitors (HMTi/KMTi), histone N-methyl lysine demethylase 
inhibitors (HDMi/KDMi), histone deacetylase inhibitors (HDACi/KDACi), and bromodomain 
inhibitors. As of 2019, there are two classes of epigenetic drugs that have been approved by FDA 
for clinical use in the United States: DNMTi and HDACi (see Table 1.2). 
The first approved epidrug in the US was azacitidine (Vidaza, Azadine), a DNMTi 
indicated to treat chronic myelomonocytic leukemia and myelodysplastic syndrome. Azacitidine 
was approved in 2004 and quickly followed by decitabine (Dacogen) with same indication two 
years later. Both drugs cause broad hypomethylation that leads to cellular dysregulation that 
most seriously affects rapidly dividing cells. It is important to note that these drugs are not highly 
locus-specific and these agents can cause hypomethylation at many genomic sites. Even though 
current drugs are designed to favorably induce genes that have been silenced in cancer (Liang et 
al. 2002), they may also activate the expression of prometastatic genes as well as oncogenes 
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(Cheishvili et al. 2015). There remains a need to develop more selective DNMTi to improve the 
efficacy and reduce side effects for this class of drug. 
The potential application of DNMTi to other diseases is also under investigation and 
examples include multiple sclerosis (Peedicayil 2016), HIV (Abdel-Hameed et al. 2016), pain 
(Sun et al. 2015) and memory (Singh et al. 2015). For example, DNMT activity was observed in 
HIV-1 infection of CD4(+) T-cells in vitro and induced hypermethylation of distinct cellular 
promoters (Abdel-Hameed et al. 2016). Studies from Rajasethupathy et al. suggested that DNA 
methylation is necessary for serotonin-dependent long-term facilitation in memory formation 
(Rajasethupathy et al. 2012). For a curative therapy of AIDS patients, a combination of 
antiretroviral drugs and epidrugs has been suggested for the reactivation of latent HIV-1 
genomes. These epidrugs include DNMTi, HDACi, histone methyltransferase inhibitors (HMTi) 
and histone demethylase inhibitors (Abdel-Hameed et al. 2016). 
The HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, vorinostat, in 2006) and 
romidepsin (depsipeptide, in 2009) have proven to be successful in cancer therapeutics (Lane and 
Chabner 2009). These agents cause the accumulation of acetylated histones and prevent 
progression of tumor cells. Vorinostat was the first HDACi to be approved by the FDA, 
indicated for cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL). 
Panobinostat is the latest HDACi approved by the FDA in 2015 and is indicated for the treatment 
of multiple myeloma in combination with bortezomib and dexamethasone. Outside the US, 
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Table 1.2. Classification of US FDA-approved epigenetic drug classes according to mechanism of action. 
i Subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by 
neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, 
refractory anemia with excess blasts in transformation. ii Including 90 previously treated and 
untreated, de novo and secondary MDS of all French-American-British subtypes 91 (refractory 
anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, 92 
refractory anemia with excess blasts in transformation, and 93 intermediate-1, intermediate-2, and 
high-risk International Prognostic Scoring System groups).iii In patients who have received at least 





In Europe, for example, only panobinostat has been approved for general clinical use (to 
treat multiple myeloma), while belinostat received orphan designation for peripheral T-cell 
lymphoma (PTCL). In China, an additional HDACi known as chidamide (Epidaza®), was 
approved for treatment of PTCL by the Chinese FDA in 2015. Although most HDACi are 
approved for cancer type indications, studies have suggested potential roles in schizophrenia 
(Kurita et al. 2012) and Type2 diabetes (Sharma and Taliyan 2016). However, similar to the 
DNMTi drugs, current HDACi have broad effects across the genome and lack locus-specificity. 
These drugs can have serious side effects (Hunter 2015) and use of currently approved HDACi 
in cancer is often indicated only after other treatments have failed, or as combination therapies 
(Table 1.2). 
Besides these two approved epidrug classes, HMTi and bromodomain inhibitors are other 
emerging epidrug classes under development. Pinometostat is a small molecule inhibitor of the 
histone methyltransferase DOT1L for the treatment of MLL-r leukemia (Daigle et al. 2013). 
Tazemetostat is an orally administered, first-in-class small molecule HMTi that targets the EZH2 
transcriptional repressor to treat multiple types of hematological malignancies and genetically 
defined solid tumors (Kurmasheva et al. 2017). GSK3326595, an inhibitor of the transcriptional 
regulator protein arginine methyltransferase 5 (PRMT5), is also in phase 1 clinical trial. 
Bromodomain proteins are readers that recognize acetylated lysine and transduce the gene 
activation signal (Filippakopoulos and Knapp 2014). OTX-015 and CPI-0610 are bromodomain 
protein inhibitors both in phase I trials for cancers. These drugs target a specific family of 
bromodomain proteins, known as Bromodomain Extra-Terminal motif (BET) proteins (Chung et 
al. 2011). Another BET inhibitor, Apabetalone (RVX-208), is in Phase III clinical trials for 
cardiovascular events in Type 2 diabetes subjects with coronary artery disease. These example 
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epidrugs, and several more are advancing through the clinical trial pipeline, are summarized in 
Table 1.3. In this table, we focus only on epidrugs in active or planned clinical trials registered 
in the US (clinicaltrials.gov) and show the latest phase trial for each drug, plus any trials for 
indications outside oncology. We restrict our listing of early phase cancer indications because 
these are too numerous to list concisely.
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High-risk type 2 diabetes 
mellitus with coronary artery 
disease 
Phase III NCT02586155 
CPI-0610 (Constellation 
Pharmaceuticals) 





INCB054329 (Incyte) Advanced malignancies Phase I/II NCT02431260 
GSK525762 
(GlaxoSmithKline) 







Advanced or recurrent solid 
tumors 









Selected advanced solid 
tumors 
Phase I NCT02698176 
TEN-010/ RO6870810 
(Hoffmann-La Roche) 
Advanced Solid Tumors; 








Phase I NCT02543879 
BMS-986158 (Bristol-Myers 
Squibb) 
Advanced Solid Tumors Phase I NCT02419417 
Mivebresib/ABBV-075 
(AbbVie) 
Advanced cancers Phase I NCT02391480 
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DNA N-Methyltransferase Inhibitor 
(DNMTi) 
Guadecitabine (Astex) Acute Myeloid Leukemia Phase III NCT02920008 
TdCyd 
(NCI) 






Advanced Hormone Receptor 
positive (HR+) Breast Cancer 
ii 









Advanced Stage Mycosis 
Fungoides or Sézary 
Syndrome 




Ovarian cancer iii Phase II NCT02948075 
 
Pracinostat/SB939 (NCIC 
Clinical Trials Group) 





















Non-Small Cell Lung Cancer 
vii 





Non-Small Cell Lung Cancer 
vii 














Myelodysplastic Syndrome Phase II 
NCT02929498 
 
Tranylcypromine (Martin Luther 
Universität) 
Relapsed/Refractory Acute 
Myeloid Leukemia viii 
































Advanced Solid Tumors or 
B-cell lymphomas 




Diffuse Large B-cell 
Lymphoma 





Myeloma, Solid Tumors 






Solid Tumors and Non-
Hodgkin’s Lymphoma 
Phase I NCT02783300 
 
Table 1.3. Classification of epigenetic drug classes in active clinical trials registered in the US (clinicaltrials.gov) according to mechanism of action. 
i In combination with Enzalutamide.  
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ii   In combination with Aromasin (Exemestene).  
iii  In combination with Paclitaxel and Carboplatin chemotherapy.  
iv  In combination with Azacitidine.  
v   In combination with Ruxolitinib.  
vi  In combination with Pomalidomide.   
vii In Combination with Nivolumab.  
viii In combination with all-trans-retinoic acid (ATRA) chemotherapy.  
ix Only patients with rearrangements involving the MLL gene.    
 
LSD1: Lysine (K)-specific demethylase 1A, DOT1L: Disruptor of telomeric silencing 1-like, EZH1 or EZH2: Enhancer Of Zeste 




Finally, several HATi are in preclinical studies at time of writing. Aberrant function of 
HATs, also called lysine acetyltransferases (KATs), is correlated with cancer and other diseases 
(Khan and Khan 2010). HATi are great candidates with potential therapeutic utility, but current 
HATi only have moderate potency and specificity and none are in clinical trial at time of writing. 
Nevertheless, some HATi have shown efficacy in preclinical studies. Compound C646 is a 
pyrazolone-containing small molecule inhibitor of the p300/CBP HAT subfamily (Bowers et al. 
2010). It has been shown to cause growth arrest in melanoma cell lines and inhibit cancer cell 
growth in prostate and lung cancer cell lines. PU139 is a pyridoisothiazolone that inhibits several 
HAT subfamilies and was shown to block neuroblastoma xenograft growth in mice (Gajer et al. 
2015). These agents and others in development are indicative that HATi are still in infancy 
relative to other epigenetic drugs, but they show enormous promise and need further investment 
to reach their potential as therapeutic compounds. 
1.3.3. Epigenetic biomarkers of drug response 
As a natural extension of pharmacogenetics, it is possible to use epigenetic biomarkers to 
predict drug response. While none have yet achieved regulatory approval for clinical use, a small 
number of examples are established in the literature. Among the best known is DNA methylation 
of the MGMT promoter. This gene encodes a DNA repair enzyme (O6-alkylguanine DNA 
alkyltransferase). Methylation in the promoter region of MGMT is associated with better 
response to alkylating neoplastic agents like temozolomide, as first shown in glioblastoma by 
Esteller et al. (2000) (Esteller et al. 2000) and later by Hegi et al. (2005) (Hegi et al. 2005). The 
mechanism of effect is as follows. Temozolamide alkylates or methylates DNA at the N-7 or O-6 
positions of guanine residues and the resulting DNA damage triggers tumor cell death. 
Hypomethylation of MGMT leads to expression of O6-alkylguanine DNA alkyltransferase, 
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which can repair the DNA damage, whereas hypermethylation leads to silencing of the gene and 
thus greater susceptibility to the drug (Figure 1.3). In addition to glioma, a role for MGMT in 
predicting response to metastatic colorectal cancer (mCRC) treatment has also been suggested 
(Fornaro et al. 2016). 
 
Figure 1.3. MGMT: O-6-methylguanine-DNA methyltransferase. The MGMT enzyme repairs 
tumor DNA damage induced by the anticancer drug temozolomide. However, if the MGMT gene 
is methylated and not expressed, the DNA damage cannot be adequately repaired leading to 
greater tumor sensitivity to temozolomide and a better clinical response. Adapted from (Kronfol 
and McClay 2019).   
 
Other published epigenetic biomarker examples include GSTP1 and BRCA1. Methylation 
of the promoter of GSTP1 is correlated with survival in breast cancer patients and may be 
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predictive of treatment efficacy with doxorubicin (Chiam et al. 2011) or DNA methyltransferase 
(DNMT) inhibitors (Dejeux et al. 2010). The BRCA1 gene plays a role in DNA damage response 
and hypermethylation of the BRCA1 promoter region may be predictive of enhanced sensitivity 
to platinum-derived drugs in cancer cell lines and xenografted tumors; it also may be predictive 
of increased time to relapse and survival in ovarian cancer patients under cisplatin treatment 
(Stefansson et al. 2012). 
The impact of epigenetics in drug response has been investigated beyond oncology. For 
example, methylation of the P2 promoter of the IGF1 gene affects transcriptional response to 
growth hormone (GH) (Ouni et al. 2016). GH is mainly used to treat children with short stature 
due to growth hormone deficiency. Ouni et al. (Ouni et al. 2016) measured P2-driven and total 
IGF1 transcripts before and 12 h after the GH injection and found an increase in P2-driven 
transcripts with a very strong inverse correlation with CG-137 methylation. This correlation 
accounted for ~ 25% of the variability in the response to GH. 
1.3.4. Epigenetic modification of drug absorption, distribution, metabolism and excretion 
(ADME) genes 
ADME genes encode transporters, plasma proteins, and drug metabolizing enzymes that 
are responsible for absorption, distribution, metabolism and excretion of xenobiotics. Genetic 
variation at ADME genes has proven extremely successful in predicting individual differences in 
pharmacokinetics, particularly in the case of drug metabolizing phenotypes associated with the 
CYP450s, as mentioned above. However, there remain large individual differences in drug 
metabolism unexplained by genetic variation that have led to the suggestion that epigenetics may 
substantially influence these phenotypes (Ivanov et al. 2012). Unfortunately, research to date has 
not yet directly addressed this question, but individual variation in epigenetic states of ADME 
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genes has been correlated with a range of outcomes. For example, Parkinson’s disease has been 
associated with hypomethylation of the CYP2E1 gene promoter in the brain (Kaut et al. 2012). 
Methylation levels at CYP1B1 (Tokizane et al. 2005) and CYP1A1 (Okino et al. 2006) have been 
associated with prostate cancer, and CYP2W1 with colon cancer (Gomez et al. 2007). 
Methylation levels at the drug transporter genes OCT1 (Schaeffeler et al. 2011) and OCT2 (Liu 
et al. 2016), responsible for the renal excretion of drugs, have been associated with renal 
carcinoma. These findings demonstrate the existence of inter-patient variability in ADME gene 
epigenetic states, some of which have functional effects on gene expression. However, the extent 
of normal epigenetic variation at these loci in the population and the extent to which it will affect 
pharmacokinetic phenotypes remains to be determined. 
1.4. Aging 
1.4.1. Aging, drug response, and adverse drug reactions 
The elderly population in the U.S comprises 15% of the total population, which translates 
to 49 million Americans aged 65 or older in 2016. This number is projected to increase to 56 
million in 2020. The older adult population has a higher mean healthcare expenditure per annum 
($5,994) than that of the rest of the population ($4,612). It is estimated that 40% of persons 65 
years of age or older take five to nine medications concurrently, while almost one fifth (18%) 
take 10 or more. Ultimately, older adults are almost seven times as likely as younger persons to 
have adverse drug reactions (ADRs) that require hospitalization (Budnitz et al. 2006). The high 
level of drug intake associated with older age makes older adults particularly vulnerable to 
ADRs, but there is strong potential to improve this situation because 80 percent of ADRs in this 
population are dose-related and thus preventable (Routledge et al. 2004). Alleviation of dose 
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related ADRs for the aging population would be advantageous for managing this population’s 
pharmacological interventions and improve their health. 
1.4.2. Personalized dosing in the elderly population 
Age-related changes to drug response are multifactorial in origin (McLachlan et al. 2009). First, 
aging effects on renal and hepatic function alter drug pharmacokinetics (PK) and 
pharmacodynamics (PD), but these functions are considered too coarse to guide dosing because 
they do not capture specific changes to drug metabolizing enzymes (Butler and Begg 2008; 
McLachlan and Pont 2012; Tan et al. 2015). Second, despite significant successes in several 
areas, particularly in oncology, genetic tools are insufficient to bring about optimal drug therapy 
in all instances (Roses 2000). Genotype-based markers are of limited utility to explain intra-
individual changes in drug response with age because they are invariant across lifespan. 
Therefore, to enable personalization of dosing in older adults, new markers of determinants of 
drug metabolism are needed (McLachlan and Pont 2012) 
1.4.3. Epigenetics of Aging 
The most well studied epigenetic modification is the methylation of carbon 5 of cytosines 
at cytosine-guanine dinucleotide (CpG) positions, termed 5-methylcytosine (5mC). A haploid 
human genome has around 28 million CpGs, or 1% of total sequence (Jabbari and Bernardi 
2004; Babenko et al. 2017). Global 5mC, or the aggregate measure of all the 5mC in the 
genome, has been consistently reported to decrease with age in humans (Gonzalo 2010; 
Unnikrishnan et al. 2018). However, studies with the ability to measure site-specific methylation 
revealed hypermethylation at some gene promoters in older persons indicating that some loci 
gain methylation while others either lose methylation or remain unchanged with age 
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(Unnikrishnan et al.; Fraga and Esteller 2007; Fraga 2009). Those genomic regions displaying 
changes with age, regardless of the direction of effect, subsequently came to be known as age-
associated differentially methylated regions (a-DMRs) (Bjornsson et al. 2008; Christensen et al. 
2009; Teschendorff et al. 2010; Bocklandt et al. 2011). a-DMRs have implications for gene 
activity. Several large-scale studies of aging in humans examined gene expression, DNA 
methylation, or both (Table 2.1) and found that not only do DNA methylation marks correlate 
with age but are also predictive of gene expression levels (Steegenga et al. 2014). As we show in 
our preliminary data (Table 2.1), human genome-wide studies of blood DNA have shown that 
genes involved in the Absorption, Distribution, Metabolism, and Excretion (ADME) of drugs are 
differentially methylated with age. However, it has not yet been established if these changes also 
occur in the liver and affect expression levels of genes involved in drug metabolism. 
Furthermore, we do not know if these changes exert any functional effect on rates of drug 
clearance in vivo. Therefore, further studies are needed to determine if a-DMRs at ADME genes 
affect drug metabolism. 
1.5. Discussion and Conclusions 
Epigenomic medicine is already here, with numerous epigenetic disease associations 
reported, six epidrugs and a handful of epigenetic biomarker tests available the US, plus a small 
number of other products available worldwide. The largest number of findings and applications 
to date is in the field of oncology. However, the field of epigenetics is only a few decades old 
and epigenomic medicine is a very recent arrival, so we are still in early days. The perceived 
benefits that epigenomics will bring to healthcare are emphatically illustrated by the large 
number of epidrugs currently in development and the large sums of research dollars spent on 
large-scale discovery efforts such as RoadMap Epigenomics. To drive the field forward, 
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epigenomic medicine needs to expand beyond cancer. Also, while significant efforts are being 
devoted to bringing new epidrugs to market, more efforts must be devoted to developing new 
epigenetic biomarkers, of which there are few. 
Several factors are currently driving innovation in epigenomic medicine. First is the general 
level of interest in the field, which is high. Second is the ongoing characterization of reference 
epigenomes to enrich and accelerate research efforts. Third is the availability of powerful 
methods such as next-generation sequencing (NGS) to characterize epigenomes. Discussion of 
technical methods is largely outside the scope of this chapter and reviews have been published 
elsewhere (Laird 2010; Krueger et al. 2012). However, with NGS approaches already in use to 
characterize genome-wide DNA methylation and protein-DNA binding patterns, we would argue 
that technology is not a bottleneck for the advancement of epigenomic medicine. 
Considering epigenomic biomarker research, among the most significant difficulties are data 
complexity and the clean interpretation of findings (Ledford 2015). Unlike studies of genotype, 
epigenomics has a direction of causality problem. While epigenetic biomarkers may be 
predictive of disease state or drug response, epigenetic changes are also inducible by 
pharmacological treatments (Feinberg 2007; Wang et al. 2007). As a result, there is the risk that 
epigenetic differences between cases and controls in an epigenome-wide association study could 
be the result of drug treatment in cases, rather than causal variation. Furthermore, evidence from 
genome-wide studies suggests that not all epigenetic changes are functional or cause identifiable 
changes to gene expression (Stricker et al. 2017). Targeting specific populations, such as drug-
naïve patients, may go some way to solving issues related to the direction of causality, but it is 
certain that experimental model systems will be needed to adequately disentangle causality and 
establish functionality of epigenetic changes. 
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Another complexity is that epigenetic modifications are cell specific. While this is in 
many ways an advantage and can give precise insight into the workings of the cell of origin, it 
also leads to some challenges in sample collection, particularly with respect to clinical studies. 
Blood DNA is the most readily-accessible source from humans, but the extent to which blood 
DNA methylation is reflective of methylation changes in other tissues is debated and it seems 
there may not be a hard and fast rule with respect to which changes are reflected in blood as 
compared to which are not. Aging epigenetic signatures, also known as the “epigenetic clock”, 
appear to transcend tissue barriers (Horvath 2013), but the extent to which a blood DNA 
methylation mark is informative about a disease of, for example, the lung or heart remains an 
open question. Circulating cfDNA is an exception, since it is sourced from the diseased tissue of 
interest and is merely liberated into the bloodstream. 
While these considerations apply to the discovery of novel epigenetic biomarkers, a 
separate set of considerations apply to novel epigenetic drugs. Paramount among priorities for 
future epidrug development is improving target specificity. This can be viewed in two ways. 
First, as mentioned above, current drugs lack genomic locus specificity and affect DNA 
methylation or histone modifications somewhat indiscriminately. To truly enable precision 
correction of aberrant changes, some sort of nucleic acid targeting adjunct is likely to be 
required. While antisense RNA (MG98) has already been used to modulate DNMT activity with 
some success (Reid et al. 2002), it is difficult to speculate how this could be used to target 
epigenetic modifications at specific target loci. On the other hand, it may be possible to 
capitalize on the locus targeting abilities of CRISPR/Cas9 systems to deliver epigenetic 
modifying agents to specific loci. Indeed, epigenome editing has already been demonstrated 
using this broad approach (Thakore et al. 2016). A second consideration involves the specificity 
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of epidrugs to specific members of families of chromatin modifying enzymes. For example, there 
are numerous human DNMTs and HDAC enzymes with somewhat different functions and 
substrate specificities but currently available DNMTi and HDACi are non-selective and inhibit 
many isozymes. However, some drugs currently in clinical trials appear to be more selective, e.g. 
mocetinostat that inhibits only HDAC 1 and 4 (see Table 1.3). Thus, the problem of specificity 
does not appear to be insurmountable. To conclude, we mention two areas, one technological and 
one clinical, that we consider to be of significant interest going forward. 
In the clinical arena, aging is an area where epigenomic medicine may make an impact. 
Older adults are at increased risk for adverse drug events and this may be partly because aging is 
associated with changes in physiology that can affect drug pharmacokinetics and 
pharmacodynamics (Fillit et al. 2017). The clinical challenge is to identify those patients who are 
more likely to experience an adverse drug event or altered drug response among the older adult 
population when weighing the risk versus the benefit of a drug therapy. Chronologic age alone is 
insufficient as an indicator that dosage adjustment or avoidance of a particular therapeutic agent 
is warranted. Pharmacogenetic information alone is also insufficient, as altered drug response 
and risk of adverse drug events changes across the lifespan while genotype remains constant 
(Brunet and Berger 2014; Pal and Tyler 2016). Epigenetic alterations may be a better indicator 
than chronological age for personalizing drug therapy for the older population. For example, it 
has been proposed that epigenetic regulation of cytochrome P450 (CYP) enzymes responsible for 
drug metabolism through DNA methylation may result in altered drug exposure in geriatric 
patients (Seripa et al. 2015). More research is needed to elucidate the relationships between 
epigenetics and drug exposure and response during senescence but is a promising alternative to 
chronologic age for adjusting pharmacotherapy in older adults. 
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Aging is associated with reduced liver function that may increase the risk for adverse 
drug reactions in older adults. We hypothesized that age-related changes to epigenetic regulation 
of genes involved in drug metabolism may contribute to this effect. We reviewed published 
epigenome-wide studies of human blood and identified the cytochrome P450 2E1 (CYP2E1) 
gene as a top locus exhibiting epigenetic changes with age. To investigate potential functional 
changes with age in the liver, the primary organ of drug metabolism, we obtained liver tissue 
from mice aged 4-32 months from the National Institute on Aging. We assayed global DNA 
methylation (5mC), hydroxymethylation (5hmC) and locus-specific 5mC and histone acetylation 
changes around mouse Cyp2e1. The mouse livers exhibit significant global decreases in 5mC 
and 5hmC with age. Furthermore, 5mC significantly increased with age at two regulatory regions 
of Cyp2e1 in tandem with decreases in its gene and protein expression. H3K9ac levels also 
changed with age at both regulatory regions of Cyp2e1 investigated, while H3K27ac did not. To 
test if these epigenetic changes are associated with varying rates of drug metabolism, we assayed 
clearance of the CYP2E1-specific probe drug chlorzoxazone in microsome extracts from the 
same livers. CYP2E1 intrinsic clearance is associated with DNA methylation and H3K9ac levels 
at the Cyp2e1 locus but not with chronological age. This suggests that age-related epigenetic 
changes may influence rates of hepatic drug metabolism. In the future, epigenetic biomarkers 







Adverse drug reactions (ADRs) are estimated to be between the fourth and sixth leading 
cause of death in the United States (Lazarou et al. 1998). The impact and management of ADRs 
are complex and has been estimated to cost up to $30.1 billion annually (Sultana et al. 2013). 
Previous research suggests that rates of ADRs increase as people age, have more chronic health 
conditions, and take more medications (McLean and Le Couteur 2004; ElDesoky 2007; Budnitz 
et al. 2011). Human life expectancy has more than doubled in the last two centuries, and while 
mortality has been delayed, aging is still accompanied by a significantly elevated risks for many 
diseases (Issa 2002; Duron and Hanon 2008; Barzilai et al. 2012). Comorbid chronic conditions 
in individuals older than 65 years cause high degree of polypharmacy in this population. 
According to a 2006 survey, 40% of persons 65 years of age or older were taking five to nine 
medications, while almost one fifth (18%) were taking 10 or more (Slone Epidemiology Center 
2006). Ultimately, older adults are almost seven times more likely than younger persons to have 
ADRs that require hospitalization (Budnitz et al. 2006). While ADRs are a serious problem in 
the aging population, up to 80% of ADRs in older patients are dose related and therefore, are 
potentially avoidable (Routledge et al. 2004). This implies that effective methods for predicting 
the correct dose for the individual patient could make a significant impact in geriatric healthcare.  
Age-associated changes to hepatic metabolism of drugs increase risk for ADRs in older 
adults (McLachlan et al. 2009; McLachlan and Pont 2012) but the determinants of these changes 
are not fully understood. One possible mechanism that may influence rates of drug metabolism 
in older adults is epigenetics (Seripa et al. 2015; Fisel et al. 2016; Kronfol et al. 2017). Aging is 
associated with substantial changes to the epigenome (Benayoun et al. 2015; Pal and Tyler 2016; 
Horvath and Raj 2018) and genes encoding drug metabolizing enzymes in human liver are under 
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epigenetic control (Bonder et al. 2014, Park et al. 2015). Furthermore, treatment with epigenetic 
drugs affects the metabolic capacity of cultured cells (Ruoß et al. 2019). These considerations led 
us to hypothesize that age-associated epigenetic changes at genes encoding drug metabolizing 
enzymes could affect rates of drug metabolism. Epigenome-wide association studies (EWAS) in 
human blood have found significant changes to DNA methylation at several genes encoding 
phase I (oxidative) drug metabolism enzymes with age (Heyn et al. 2012; Hannum et al. 2013; 
Horvath 2013; Steegenga et al. 2014; Reynolds et al. 2014; Marttila et al. 2015; Peters et al. 
2015). However, the extent to which these age-related changes are present and affect enzymatic 
activity in the liver, the primary site of drug metabolism, is unclear. Therefore, the goal of this 
study is to identify age-related epigenetic changes at phase I genes encoding drug metabolizing 
enzymes in the liver and test if these epigenetic changes are associated with rates of drug 
metabolism. Due to the experimental control afforded and availability of the relevant tissue, we 
chose to conduct the experiments in mice. 
To date, the number of published studies on epigenetics and drug metabolism in aging is 
limited. As a starting point to identify potential genes of interest, we reviewed published EWAS 
and genome-wide gene expression studies in human blood and chose the phase I drug 
metabolism genes showing the best empirical evidence of change with age. The rationale for 
using human blood studies to guide gene selection is because 1) the largest number of aging 
EWAS have been conducted in this tissue, 2) epigenetic aging effects are significantly correlated 
across tissues and species (Horvath 2013) and 3) consistent patterns of gene expression changes 
with age have been observed across several species (McCarroll et al. 2004). We identified two 
phase I drug metabolism genes, CYP2E1 and CYP1B1, showing strong evidence for age-
associated epigenetic changes in human blood. We mapped the associated regions in the human 
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genome to their homologous mouse regions and tested for epigenetic changes in mouse liver. 
Only Cyp2e1 showed differential methylation with age. Based on these results, we focused on 
Cyp2e1 and conducted a detailed analysis of regulation at this locus including assays for DNA 
methylation and histone post-translational modifications (PTMs) with reported associations with 
age (McClay et al. 2014; Dozmorov 2015). Finally, we investigated if these effects were 
associated with CYP2E1 metabolic function by isolating liver microsomes and applying 
Michaelis–Menten kinetics to determine the intrinsic clearance (CLint) of the probe drug 
chlorzoxazone (CZ), which is predominantly metabolized by CYP2E1 (Lucas et al. 1999).  
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2.3.  Methods 
2.3.1. Mice: Liver tissue samples from 20 male CB6F1 mice (5 subjects in each of four 
age groups 4, 18, 24, and 32 months) were obtained from the National Institute on Aging (NIA) 
tissue bank.  
2.3.2. DNA and RNA extraction: Genomic DNA was extracted using the AllPrep 
DNA/RNA kit (80204, Qiagen, Hilden, Germany) according to manufacturer’s protocol. DNA 
and RNA purity and quantity were measured using a Nanodrop spectrometer (ThermoFisher, 
Waltham, MA).  
2.3.3. Global 5-MethylCytosine (5mC) and 5-HydroxymethylCytosine (5hmC): Global 
5mC and 5hmC levels were measured using ELISA colorimetric assays by MethylFlash kits 
(1030-96, 1032-96, Epigentek, Farmingdale, NY). 5mC- or 5hmC-specific antibodies, provided 
in the kit, were incubated with 100ng genomic DNA. Optical density at 450 nm was measured on 
a Synergy HT plate reader (BioTek Instruments, Winooski, VT). Known standards provided in 
the kit consisting of 0.1, 0.2, 0.5, 1, 2, and 5% for 5mC and 0.02, 0.04, 0.1, 0.2, 0.4, and 1% for 
5hmC were also assayed. The optical density of liver samples was used to determine the 
percentage of 5mC and 5hmC of each sample by interpolation on respective standard curves. 
Each unknown and standard was run in duplicate. 
2.3.4. Selection of genomic regions of interest: Aging EWAS findings for human blood 
were obtained from published studies (see Dozmorov 2015) and genes encoding drug 
metabolizing enzymes were obtained from the ADME (absorption, distribution, metabolism, and 
excretion) gene list from the pharmaADME consortium (pharmaADME.org), see Table 2.1. 
Significant findings by ADME gene were summed across studies and the top two phase I drug 
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 Exp Exp Meth Meth Meth Meth Both Both Total 
Phase I genes  
CYP2E1 X X   X   X 4 
CYP1B1 X X X    X  4 
CYP2J2  X  X     2 
CYP1A1 X       X 2 
ADHFE1  X   X    2 
PDE3B  X    X   2 
DHRS9  X     X  2 
CYP2D6 X        1 
CYP3A4         0 
 
Table 2.1. Summary of human EWAS findings for phase I drug metabolism genes. Human ADME genes list from pharmaADME 
(www.pharmaadme.org) was contrasted on the top findings from EWAS and gene expression studies of normal aging in human blood 
DNA. Genes encoding phase I drug metabolizing enzymes that showed significant association in the top findings of these studies is 
marked with an “X”. The total number of studies were a specific gene is a top association in the reported results is shown as a total in 







Genomic location of human age-associated Cytosine-phosphate-Guanine (CpG) positions 
were used to extract the homologous regions in mouse using the “convert” function in the 
University of California Santa Cruz (UCSC) genome browser (Kent et al. 2002). A complete list 
of the genomic coordinates of all investigated regions in mouse can be found in Table 2.2. An 
additional regulatory region around human CYP2E1 was identified using the GeneHancer track 
(Fishilevich et al. 2017) on the UCSC genome browser (Figure 2.1). Data from the mouse 
Encyclopedia of DNA Elements (ENCODE) (Stamatoyannopoulos et al. 2012) and Ludwig 
Institute for Cancer Research (LICR) (Barrera et al. 2008) chromatin immunoprecipitation 
(ChIP) sequencing runs on young (8 weeks) male mouse liver tissue were used to identify two 
regions with high levels of histone 3 lysine 9 acetylation (H3K9ac) and histone 3 lysine 27 





Table 2.2. HRM and ChIP primers and qPCR product sequences. Primers used in the High-Resolution Melt and Chromatin 
Immunoprecipitation Quantitative Polymerase Chain Reaction assays with size of PCR product, genomic coordinates, and assembly 
with CpG count when appropriate. a blasted from Pace et al., 2018 to obtain coordinates
Gene 
Primers (5’→ 3’) 
Product size/coordinates/assembly  
Forward Primer Reverse Primer 
 High-Resolution Melt CpG count 
Cyp2e1 AATTAGTATTTTAGGTTAAGGGAGATGAGTGG TCCCTTACCTTAATTAAAAACTTAAAAATATCCTTC 319/chr7:147,949,616-147,949,934/mm9 7 
Cyp1b1 TGTTTTGTTGTATTAGGGTTTGGTGGATGG CCTTTATATCCCCAACATAACCACCAAC 350/chr17:80,113,318-80,113,667/mm9 21 
 Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction    
Cyp2e1  
Region 1 ATGCTGAGCCAGCTGTGA CCACATGCAAAGACAATCCT 145/ chr7:147,950,223-147,950,367/mm9  




AGAGAGGGAGGAGGGGAAATG AACAGGGAGGAGCAGAGAGCAC 200/ chr6:125,115,604-125,115,803/mm9 a  
Negative 
control 




Figure 2.1 Illustration showing the transcription start site (TSS) and upstream regulatory regions of the human CYP2E1 and the 
homologous mouse Cyp2e1 gene. Upstream regulatory element positions were obtained from GeneHancer (Fishilevich et al. 2017) 
and ORegAnno (Lesurf et al. 2016). DNA methylation assays were conducted in the current study at both the TSS and upstream 
regulatory region in mouse at positions marked by the arrows. Reference histone 3 lysine 9 acetylation (H3K9ac) and histone 3 lysine 
27 acetylation (H3K27ac) in 8-week-old mouse livers are from the ENCODE/LICR track in UCSC Genome Browser. Two loci with 
high liver histone acetylation levels were chosen for analysis using ChIP-qPCR in the current study, at positions marked by the 






Region Cyp2e1 Region 1 Cyp2e1 Region 2 
Product size/coordinates/assembly 275/chr7:147,949,576-147,949,850/mm9 157/ chr7:147,942,437-147,942,593/mm9 






Sequencing primer 5’ATTTTTATAGATTTGTTTTTAGATG3’ 5’GTTGGAGTTTAATGGGA3’ 
M13 primer a 5’biotin-CGCCAGGGTTTTCCCAGTCACGAC3’ 
CpG count 7 1 
 
 
Table 2.3. Pyrosequencing primer sequences. Primers used in the Pyrosequencing assays of region 1 and 2 with size of pyrosequenced 
PCR product, coordinates, and assembly with CpG count. aM13 primer sequence published in Royo et al. 2007.
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2.3.5. Bisulfite conversion of genomic DNA and High-Resolution Melt (HRM) analysis: 
200ng of liver genomic DNA was treated with sodium bisulfite according to the EZ DNA 
Methylation kit protocol (D5002, Zymo Research, Irvine, CA). Mouse genomic DNA of 5 and 
85% methylation were used as standards (808063, 808064, EpigenDx, Hopkinton, MA). Ratios 
of the standard DNA were mixed at 5, 25, 45, 65, and 85% to create a standard curve. A negative 
(no template) control was also used per plate. High-Resolution Melt (HRM) assays using 
MeltDoctor HRM MasterMix (4409535, Applied Biosystems, Foster City, CA) on a Quantstudio 
3 instrument were used to measure 5mC levels at LINE1 elements using the method of Newman 
et al. (2012) with minor modifications and at a 319 base pair region on the 5’UTR of mouse 
Cyp2e1 (chr7:147,949,616-147,949,934, mouse genome assembly mm9 NCBI37/ build 9, July 
2007) encompassing 7 CpGs (Table 2.2). For Cyp2e1, samples were amplified by qPCR as 
follows 10min hold at 95ºC followed by 40 cycles of: 15sec at 95ºC, 30sec at 57ºC and 30 sec at 
72ºC, followed by a final extension at 72ºC for 7 min and a melt curve stage with temperature 
range of 57ºC to 95ºC with fluorescence capture at 0.025 degrees per second increment. Each 
reaction included 20ng bisulfite-converted DNA and final concentration of 1X MeltDoctor HRM 
MasterMix (Applied Biosystems), 0.2µM forward and 0.2µM reverse primer (Table 2.2).  
HRM LINE1 assay was performed as described previously (Newman et al. 2012) with 
slight adjustments. MeltDoctor HRM MasterMix (Applied Biosystems, Foster City, CA) on a 
Quantstudio 3 instrument was used to measure 5mC levels at the 193 base pair LINE1 region 
reported in Newman et al encompassing 11 CpGs. Samples were amplified by qPCR as follows 
10min hold at 95ºC followed by 45 cycles of: 15sec at 95ºC, 60sec at 60ºC, followed by a melt 
curve stage with temperature range of 60ºC to 95ºC. Each reaction included 20ng bisulfite-
converted DNA and 0.75µM each of unmethylated forward and reverse primer (Newman et al. 
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2012) in 1X MeltDoctor HRM MasterMix. Standards of 0, 25, 50, 75, 100% methylation 
(EpigenDx, Hopkinton, MA) were run in duplicate while the liver samples were run in triplicate. 
The NTS values (Newman et al. 2012) of the liver samples were interpolated on the standard 
curve to yield their 5mC percentage. 
 2.3.6. Gene expression analysis by reverse transcription – quantitative PCR (RT-qPCR): 
For each sample, 1µg of total liver mRNA was reverse transcribed to cDNA by iScript kit 
according to manufacturer’s protocol (1708891, Bio-Rad, Hercules, CA). Aliquots of cDNA 
were amplified in triplicate using final concentration of 1X TaqMan master mix (4369016, 
Applied Biosystems) and 1X TaqMan Cyp2e1 Mouse Gene Expression Assay 
(Mm00491127_m1, ThermoFisher) (Martinez et al. 2010; Koh et al. 2011). qPCR conditions 
were as follows 40 cycles of 15 sec at 95ºC and 60 sec at 60ºC. Mouse Gapdh endogenous 
control was also assayed in triplicate (Mm99999915_g1, ThermoFisher) (Scarzello et al. 2016; 
Wilhelm et al. 2016; Jia et al. 2018). A 1:2 serial dilution of control cDNA was used to generate 
a 5-point standard curve. Quantification cycles (Cq) were determined using the Relative 
Quantification application on the ThermoFisher Cloud. Normalized quantification cycles (ΔCq) 
were obtained by subtracting the mean Gapdh Cq from the mean Cyp2e1 Cq. ΔΔCq was 
calculated for each age group by subtracting the ΔCq of the 4 months (youngest age group as 
reference) from each of the other age group’s ΔCq to calculate fold differences. 
2.3.7. Western Blots: Cell protein lysates were created from homogenization of 20mg 
liver tissues in 200µL Pierce RIPA buffer (89900, Thermo Fisher, Waltham, MA) with final 
concentration of 1% v/v (2 µL) Halt Protease Inhibitor buffer (78430, Thermo Fisher, Waltham, 
MA). The Pierce BCA assay (23227, Thermo Fisher, Waltham, MA) was used to measure 
protein concentrations using manufacturer’s standard protocol. Absorbance at 562nm was 
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measured on a Synergy HT plate reader and the unknown protein concentration was determined 
by interpolating absorbance of unknown samples on an 8-point standard curve created from 
diluted albumin standards.  
10µg of total protein in 30µL β-Mercaptoethanol (βME)-Laemmli buffer (1610710, 
1610747, Bio-Rad) were separated on 10% Mini-PROTEAN precast SDS-PAGE gels (4568033, 
Bio-Rad) at constant 200V for 35min and transferred onto PVDF membrane using a TransBlot 
Turbo (1704150, Bio-Rad) at 1.3A for 5 min. Membranes were blocked for 30 min in 5% milk in 
1X TBST (Tris Buffered Saline, Tween20). Blots were probed using anti-CYP2E1 primary 
antibody (1:2500, ab28146, Abcam) in 10mL 5% Milk in 1X TBST at 4ºC overnight and washed 
three times with 1X TBST the next day. The blots were incubated with HRP-coupled rabbit IgG 
secondary antibody (1:10000, Cell Signaling, Danvers, MA) and 0.5µL Precision Protein 
StrepTactin-HRP conjugate (Bio-Rad) for 1hour at RT in 10mL 5% Milk in 1X TBST. 
Membranes were washed five times with 1X TBST. Blots were treated with 2mL Clarity 
Western ECL (1705060, Bio-Rad) at 1:1 clarity western luminol enhancer: peroxide solution 
ratio to start chemiluminescence and imaged 2min afterwards on the ChemiDoc Touch (Bio-
Rad). Blots were washed with 1X TBST and stripped for 30min using Restore stripping buffer 
(21059, Thermo Fisher). After stripping, the membrane was incubated with GAPDH primary 
antibody (1:5000, MA5-15738, Thermo Fisher) and then mouse IgG secondary antibody 
(1:20000, 7076S, Cell Signaling, Danvers, MA). The bands were visualized at 49 and 37 kDa for 
CYP2E1 and GAPDH respectively using Image Lab software v 6.0 (Bio-Rad, Hercules, CA). 




2.3.8. Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction (ChIP-
qPCR): 80 mg of mouse liver was minced into 1 mm3 fragments with -20 C precooled scalpel 
and transferred to 2mL Eppendorf tube. TruChIP tissue shearing kit (520237, Covaris, Woburn, 
MA) was used to prepare sheared chromatin. Centrifugations were at 200g for 5 min at 4ºC 
unless otherwise noted. The minced tissue was washed with 1 mL 1X cold PBS and centrifuged 
at 200g for 5min at 4ºC. The supernatant was discarded and 1mL of fixing buffer A was used to 
resuspend the pellet. 100µL of freshly prepared 11.1% methanol-free formaldehyde (1% final 
concentration) was added and the fixation was quenched after 2 min with 58µL quenching buffer 
E. The suspension was centrifuged, and the supernatant discarded. Pellet was washed twice with 
1mL 1X cold PBS and centrifuged. Pellet was transferred to tissueTUBE (TT05M XT) provided 
in the kit and flash frozen in liquid nitrogen for 45sec and pulverized into powder by a precooled 
pestle. Pulverized tissue was transferred by inverting to a screwed-on milliTUBE-2mL and 
stored at -80ºC until nuclei separation and shearing step the next day. Pulverized tissue was 
transferred to a 2mL Eppendorf tube using two successive transfers by 500µL lysis buffer B. The 
2mL tube was incubated on a rotor at 4ºC for 20min to complete lysis. Nuclei were pelleted by 
centrifugation at 1700g for 5min at 4ºC. Supernatant was discarded and pellet was resuspended 
in 1mL wash buffer C and incubated on a rocker for 10min at 4ºC. Nuclei were pelleted again at 
1700g for 5min at 4ºC and supernatant discarded. Pellet was resuspended with 1mL wash buffer 
C and centrifuged at 1700g for 5min at 4ºC. Pellet was resuspended with 1mL shearing buffer 
D2 and sheared on M220 (Covaris, Woburn, MA) for 8min at 75 PIP, 10% duty factor, 200CPB, 
7C set point temperature (4/10 Min/Max), and no degassing. Time course trials were conducted 
to determine optimal shearing (2-20 min) and fixation times (2 and 5 min) of 8 and 2 min 
respectively which yielded the highest percentage (>75%)  of fragment sizes between 150 and 
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700 bp and the lowest percentages (<25%) of fragment sizes less than 150 and higher than 701 
bp combined. Shearing and fixation time course trials were analyzed on the Agilent 2100 
Bioanalyzer using the Agilent DNA 12000 chip on Agilent 2100 expert software. 25µL of 
sheared chromatin was incubated with 1µL 10mg/ml RNAse (EN0531, Thermo Fisher, 
Waltham, MA) at 37ºC for 30min, then it was treated with 4µL 10mg/ml Proteinase K (17916, 
Thermo Fisher, Waltham, MA) at 65ºC overnight (16 hours). DNA was purified using QIAquick 
PCR purification Kit (Qiagen, Hilden, Germany). The concentration of eluted DNA was 
measured on Qubit 4.0 fluorometer and used to calculate the volume required to have 2µg 
sheared chromatin as starting material for the Chromatin immunoprecipitation (ChIP) step (1:1 
ratio of DNA to chromatin was used to calculate chromatin concentration). The sheared 
chromatin was diluted 1:2 with 3X Covaris IP dilution buffer in order to decrease final SDS 
concentration to 0.083% and prevent SDS interference with epitope and antibody binding.  
Each ChIP had 2µg of sheared chromatin. 2% of the volumes of sheared chromatin per IP 
was set aside at 4ºC as input control and was not processed through ChIP step. ChIP was carried 
out by incubating 5 µL of H3K9ac (39137, Active Motif, Carlsbad, CA), or 5µL of H3K27ac 
(39133, Active Motif, Carlsbad, CA), or 5µL of Rabbit IgG (ab171870, Abcam) with 2µg 
sheared chromatin from each sample overnight (16 hours) at 4ºC. Hence, three worth of ChIP 
volumes were used from each sample. The formed complex was incubated with 50 µL 
Dynabeads Protein G (10003D, Thermo Fisher, Waltham, MA) for 4 hours at 4ºC. The bead 
linked complex was inserted on the DynaMag (Thermo Fisher, Waltham, MA) magnet rack for 2 
min and the supernatant discarded. The bead coupled complex was removed from the magnet 
and washed 3 times with 500 µL with cold 0.05X Tween 20 in PBS PH7.4 (10010023, Thermo 
Fisher, Waltham, MA) for 3 min each at room temperature on HulaMixer (Thermo Fisher, 
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Waltham, MA). Finally, 50 µL of IP elution buffer (Aq. 1% SDS, 0.1 M NaHCO3, pH 9.0) was 
added to the bead coupled complex and incubated on a heat block for 1hour at 65ºC with 15sec 
vortexing every 15 min. The samples were then inserted back on the DynaMag for 2 min and 50 
µL of the supernatant was transferred to a 96 well PCR plate. The input control was diluted 1:2 
with 3X Covaris IP dilution buffer to mimic the dilution done to the samples and preserve its 
percentage (2%). The ChIP’ed samples and their input controls were incubated each with 2 µL 
RNAse for 30 min at 37C and then 8 µL of Proteinase K was added and incubated overnight (16 
hours) at 65ºC. The next day, DNA was purified using QIAquick PCR purification kit (Qiagen, 
Hilden, Germany) to final elution volume of 50 µL. 2 µL of each DNA elution (H3K9ac, 
H3K27ac, IgG, and input control) per sample was used per qPCR reaction.  
Each ChIP’ed DNA was amplified in triplicate using PowerUp SYBR Green (A25742, 
Applied Biosystems), with 0.2 µM of forward and reverse primers (Table 2.2) as follows: 2min 
at 50ºC, 2min at 95ºC followed by 40 cycles of: 15sec at 95ºC, 30sec at 59ºC and 1min at 72ºC, 
followed by melt curve stage. This stage is as follows: 15sec hold at 95ºC followed by 1min hold 
at 59ºC and then the continuous fluorescence acquisition starts while increasing the temp by 
0.15ºC/s to end at 95ºC followed by a 15sec hold at 95ºC. Primer specificity and efficiency were 
tested on 2% agarose gel and a 5-point 1:2 serial dilution standard curve respectively. No 
secondary amplification or primer dimers were detected indicating primer specificity. A singular 
melt peak was shown by the qPCR melt curves indicating formation of a single product. Primer 
efficiency outside of accepted ranges [90-110] were discarded until reaction conditions were 
optimized. Cq values for each plate were downloaded and the mean threshold cycle (Cq) 
obtained for each sample and normalized to the dilution factor (2%=1/50) corrected Cq value 
(Log2 (50) =5.6438) of the input control to obtain ΔCq. The percentage of input was calculated 
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by multiplying 100 with 2 raised to the exponent of Delta Cq. For each sample, three “percentage 
of input” values were obtained and are H3K9ac, H3K7ac, and IgG. 
2.3.9. Pyrosequencing:  Quantitative methylation measures of individual CpGs were 
assessed with Pyrosequencing of bisulfite converted DNA (Tost et al. 2003). Primers targeting 
the loci of interest were designed with PyroMark Assay Design version 2.0.1.15 (Qiagen) (see 
Table 2.3 for details). The first pyrosequencing assay amplified a 257 base pair product at 
Cyp2e1 5’UTR (chr7:147,949,576-147,949,850/mm9) that encompasses 7 CpGs (Position 2-8) 
chr7: 147,949,679 - 147,949,684 - 147,949,743 - 147,949,754 - 147,949,770 - 147,949-791 - 
147,949,806, mm9. The second assay amplified a 157 base pair product at Cyp2e1 promoter 
(chr7:147,942,437-147,942,593, mm9) that encompass 1 CpG (Position 1) chr7: 147,942,492, 
mm9. Amplification was performed using the PyroMark PCR Kit (978703, Qiagen) and the 
vendor specified program for bisulfite converted DNA. The final concentrations in the PCR 
reaction mixture as follows: 1x PyroMark PCR Master Mix, 1x CoralLoad Concentrate, 1.5mM 
MgCl2, 1x Q-Solution, 10 ng of bisulfite modified genomic DNA, and 0.2µM of Forward, 
0.2µM Reverse, and 0.2µM biotinylated M13 (Royo et al. 2007) primers (Table 2.3). 2µL of the 
PCR product was separated by 2% agarose gel electrophoresis to confirm correct product size 
and absence of primer dimers and secondary amplification. The 2% agarose gel was made with 
the following ratio to obtain 0.75mm thickness in the Owl EasyCast B2 Mini Gel Electrophoresis 
System cast (Thermo Fisher Scientific, Waltham, MA): 2.52 g of agarose powder (BP2410-100, 
Fisher Scientific, Hampton, NH) and 1.89 µL ethidium bromide (BP1302-10, Fisher Scientific, 
Hampton, NH) in 126 mL 0.5X Tris-Borate-EDTA (TBE) buffer (95:5, H2O:10XTBE (BP1333-
4, Fisher Scientific, Hampton, NH)) mixed until complete gelling of agarose. The gel was poured 
onto cast and let to solidify for 30 min at RT. The cast was filled with 400 µL 0.5X TBE buffer. 
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Each gel had 2µL of 100 bp DNA ladder in the first and last well of the gel. The gel was run on 
constant voltage of 100V for 1 hour. The gel was imaged on ChemiDoc Touch (Bio-Rad, 
Hercules, CA) using default settings of auto optimal exposure for ethidium bromide stained gels.  
Next, 5µL of PCR amplicon were bound with 2µL to Streptavidin Sepharose beads (45-
000-279, Fisher, Hampton, NH) by shaking for 5 min in 40 µL Binding buffer (979006, Qiagen, 
Hilden, Germany) and 33µL of molecular biology grade water. The complex was transferred to a 
96-well HS plate (979101, Qiagen, Hilden, Germany) containing 12µL per well of final 
concentration of 0.3µM of sequencing primer in Annealing buffer (979009, Qiagen, Hilden, 
Germany) on the PyroMark Q96 vacuum preparation station. The HS plate was inserted on the 
PyroMark Q96 MD and the PyroMark Gold Q96 reagents (972804, Qiagen, Hilden, Germany) 
were used for each assay to sequence the PCR product. Each pyrosequencing assay was run 
duplicate for each sample. A standard consisting of 0, 5, 10, 25, 50, 75, and 100% methylated 
mouse genomic DNA was included on each plate (808060M, EpigenDx, Hopkinton, MA). Both 
the standard and the liver test samples were pyrosequenced in duplicates. 
2.3.10. CYP2E1 intrinsic clearance: Mouse Liver Microsomes (MLM) were prepared as 
described previously (Knights et al. 2016). 500 mg of liver tissue was homogenized using the 
Fisher 150 homogenizer (15340167, Fisher Scientific) on high speed in cold 10 mL microsome 
preparation buffer (10 mM potassium phosphate, pH 7.4, 1.15% (w/v) potassium chloride) 5 
times for 30 sec each with 30 sec breaks in between on ice and centrifuged at 700g for 10 min 
and 10,000g for 10min at 4ºC on the Optima l-90K ultracentrifuge using the SW41 rotor. The 
supernatant was ultracentrifuged at 100,000g for 75min at 4ºC and the microsome pellet 
transferred to a precooled 5mL Potter-Elvehjem grinder, ground for 1 min at low speed with 10 
strokes, transferred back into microsome preparation buffer, and the ultracentrifugation and 
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grinding steps repeated. The suspension containing the microsomes was stored at -80ºC. 10µL of 
the microsome suspension was used to measure microsomal protein concertation by the 
microplate procedure of the BCA assay (23227, Thermo Fisher). 
Standards for CZ and 6-OH-CZ (18869, 10009029, Cayman Chemical, Ann Arbor, MI) 
were purchased. Chromatographic separation was achieved using an Agilent 1100 series HPLC 
(Agilent Technologies, Santa Clara, CA) system equipped with PerkinElmer series 200 degasser 
and auto injector (PerkinElmer, Waltham, MA) and C18 BDS hypersil 50 mm x 4.6 with 5µm 
particle size (28105-054630, ThermoFisher) column. Diode array detector was used to monitor 
the depletion of CZ and the formation of 6-OH-CZ at the wavelengths 280 and 299 nm for CZ 
and 6-OH-CZ respectively. Isocratic gradient elution was used with the initial mobile phase 
being 85% aqueous (2% acetic acid (BDH20108.292, VWR, Radnor, PA) and 1% triethylamine 
(A12646 Alfa Aesar, Tewksbury, MA), v/v) and 15% methanol (A452-4, Fisher Scientific) 
(Table 2.4).  
 
Table 2.4. HPLC parameters. Chromatography parameters of the isocratic gradient co-elution 
and detection method of Chlorzoxazone and 6-hydroxychlorzoxazone. A is the aqueous mobile 
phase (2% acetic acid and 1% trimethylamine v/v). B is organic mobile phase (HPLC grade 
methanol).  
Chromatographic conditions   
Column BDS Hypersil C18 (50 x 4.6 mm, 5µm)  
Column temperature 35 ºC  
Flow rate 1.0 mL/min  
Wavelength CZ at 280 nm, 6-OH-CZ at 299 nm  
Injection volume 80 µL  
Run time 6.5 min  
   
Time (minute) A (%) B (%) 
0 85 15 
1.5 85  15 
1.6 75 25 
5 75 25 
5.1 85 15 
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Total run time was 6.5 min with retention times of 1.86 and 5.17 min for 6-OH-CZ and 
CZ respectively. Linear standard curves with R2 ≥ 0.999 were obtained from 0.47-240 µM for 6-
OH-CZ and 2.34-1200 µM for CZ (Figure 2.2 and 2.3).  
 
Figure 2.2 Chlorzoxazone standard curve. High performance liquid chromatography coupled 
with Ultraviolet detection method linearity for parent probe drug Chlorzoxazone. Linear range 
established at 2.34-1200 µM. Scatter plot with linear regression line of peak area intensity 
(mAU.s) against chlorzoxazone concentration (µM).  
 
Figure 2.3 6-hydroxychlorzoxazone standard curve. High performance liquid chromatography 
coupled with Ultraviolet detection method linearity for metabolite 6-hydrozychlorzoxazone. 
Linear range established at 0.47-240 µM. Scatter plot with linear regression line of peak area 
intensity (mAU.s) against 6-hydroxychlorzoxazone concentration (µM). 
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Hydroxylation of chlorzoxazone (CZ) to 6-hydroxychlorzoxazone (6-OH-CZ) was 
measured to determine the catalytic activity of CYP2E1. Linearity of metabolite formation with 
time and MLM protein concentration established (Figure 2.4 and 2.5). The final concentrations 
in the metabolic reactions were 50 mM potassium phosphate buffer pH 7.4, 10 mM MgCl2, 1 
mg/ml MLM protein, 1 mM EDTA (E4884, Sigma, St. Louis, MO), 1mM NADPH (AK1395, 
AkronBiotech, Boca Raton, FL),  0.5% DMSO (16785, Acros Organics), with incubation time of 
25 min at 37 ºC. The final concentration of DMSO in each reaction was maintained at 0.5%. 
Each MLM sample was run in 8 MLM reactions that vary by the final concentration (10, 20, 40, 
80, 160, 320, 640, 1000 µM) of the parent probe drug (CZ) to determine Michaelis-Menten 
kinetic constants. The reaction was stopped with equal volume (150µL) of HPLC grade 
methanol (A452-4, Fisher Scientific, Hampton, NH) and centrifuged for 10 min at 20,000g at 
room temperature. The supernatant was transferred to 96-well plate and 80 µL was injected into 
the High-Performance Liquid Chromatography (HPLC) system.  
Reaction rates (pmol/min/mg protein) of 6-OH-CZ formation were plotted against CZ 
concentration (µM), and Km and Vmax values were estimated by GraphPad Prism using equation 
1 (Eq1), were Y is the reaction rate (pmol/min/mg protein), X is CZ concentration (µM), Vmax is 
the maximal reaction rate of 6-OH-CZ  formation (pmol/min/mg protein), and Km is CZ 
concentration at half maximal rate (µM).  Eq1. Y =  Vmax ∗ X ÷ (Km +  X) 
Intrinsic clearance (CLint) is the enzyme-mediated activity toward a drug that would 
occur at concentration below Km without physiological limitations such as hepatic blood flow 
(Houston 1994). CLint by CYP2E1 for the hydroxylation reaction was calculated according to 





Figure 2.4 Metabolite formation against time plot. Line plot of 6-hydroxychlorzoxazone (6OH-
CZ) concentration (µM) against tested total microsome reaction time (min). n=3 for each time 
point. 
 
Figure 2.5 Metabolite formation against microsome protein plot. Line plot of 6-
hydroxychlorzoxazone (6OH-CZ) concentration (µM) against tested final Mouse Liver 




2.3.11. Statistics: Linear regression and Pearson correlation tests were conducted in R 
version 3.6.1 (www.r-project.org) with α=0.05. Beta values (β) and Pearson correlation 
coefficients (r), are reported. β indicates the degree of change in the outcome variable for every 
unit change in the predictor variable, while r indicates the degree of association found in the 










 2.4.1. Global epigenetic effects in aged mouse liver 
DNA and RNA extractions from the mouse liver samples were successful with an 
average 260/280 value of 1.94 [1.8-2.1] for DNA and 2.05 [1.94-2.1] for RNA. Prior to locus-
specific analysis, we first assayed age-associated changes to the global abundance of epigenetic 
marks in mouse liver. Using ELISA assays, we observed a significant decrease in global 
abundance of 5mC (β=-0.011, SE=0.004, p=0.024) and 5hmC (β=-0.001, SE=0.0004, p=0.002) 
(Figure 2.6 a, b). This translates to approximately 50% reduction in the 32months age group 
compared to the 4 months group for both modifications (0.6% v 0.32% for 5mC and 0.1% v 
0.06% for 5hmC). We also measured 5mC at LINE1 elements using High-Resolution Melt 
(HRM) analysis of bisulfite converted DNA (Figure 2.7 and 2.8). We observed a significant 
decrease in abundance of 5mC at LINE1 elements with increasing age in our sample (β= -2.062, 
p= 1x10-8), with an average reduction of 2% methylation per month of age. These results 
demonstrated that, in a broad sense, epigenetic changes were occurring with age in this study’s 





Figure 2.6 Box plots with regression line (blue) of Age-Associated changes to global (a) 5-
MethylCytosine (n=20), (b) 5-HydroxymethylCytosine (n=20). Data represent median (middle 
hinge), 25% (lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower 
1.5 * Inter Quantile Range are represented as individual black dots. (c) Scatter plot of 5-





Figure 2.7 LINE 1 methylation percentage per age. Box plots with regression line (blue) of age-
associated changes to LINE 1 methylation percentage (n=20). Data represent median (middle 
hinge), 25% (lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower 







Figure 2.8 Representative melt curves per age. Aligned melt curve from the LINE-1 High-
Resolution Melt assay showing representative curves for ages 4, 18, 24, and 32 months. Melt 





2.4.2. Age-associated changes to Cyp2e1 5’UTR methylation and gene and protein 
expression 
 We reviewed published EWAS and genome-wide gene expression studies of aging in 
human blood (Table 2.1) and identified CYP2E1 and CYP1B1 as the phase I drug metabolism 
genes showing most evidence for age-associated changes. We mapped the human age-associated 
differentially methylated regions from EWAS to their homologous mouse regions and tested for 
epigenetic changes at these loci in our aged mouse liver samples. The human CYP2E1 region 
mapped to the mouse Cyp2e1 5’UTR (Figure 2.1) and HRM analysis revealed that methylation 
at this locus increased significantly with age in mouse liver DNA (β=1.3, SE=0.0038, p=0.002) 
(Figure 2.9 a). However, no changes to Cyp1b1 methylation were observed with age (Figure 
2.10) so we focused on Cyp2e1.  
The observed Cyp2e1 5’UTR methylation increase with age corresponds to a 1.3% 
increase in methylation per month of increased age. In tandem, Cyp2e1 gene expression 
decreased significantly with age in the same samples (β= -0.03, SE=0.011, p=0.01) (Figure 2.9 
b). Using the 4 months group as reference, we observed a 2.15% reduction in expression of 
Cyp2e1 per month of increased age. Furthermore, we observed a significant decrease of CYP2E1 
protein expression with age, as measured by change in chemiluminescence detected in Western 





Figure 2.9 Box plots with regression line (blue) of Age-Associated changes to Cyp2e1 (a) 5’UTR percent methylation (n=19), (b) 
gene expression (n=20). (c) Box plot of Age-Associated changes to Cyp2e1 protein expression with representative western blot 
(n=20). Data represent median (middle hinge), 25% (lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower 





Figure 2.10 Cyp1b1 5mC with age. Boxplot showing no changes to methylation at Cyp1b1 as 
age increases from 4 to 32 months. 
2.4.3. Base-resolution 5mC analysis of Cyp2e1 5’UTR and upstream regulatory region  
 Having established that DNA methylation changes were occurring with age at the Cyp2e1 
5’UTR, we aimed to obtain a fuller picture of Cyp2e1 epigenetic regulation. Our first priority 
was to assay 5mC levels at each of the seven CpGs in the 5’UTR region individually, in contrast 
to the aggregate measure obtained via HRM. We also identified an upstream regulatory region in 
human CYP2E1 (Figure 2.1) that we used to obtain the homologous region in mouse that 
harbored a single CpG. Therefore, we subjected both regions to bisulfite pyrosequencing that 
allows highly quantitative methylation measurements at single-base resolution. This revealed 
that the single CpG in the upstream regulatory region (position 1, chr7: 147,942,492, mm9) was 
significantly hypermethylated with age (p=0.023, Figure 2.11 a & b, position 1). 
Pyrosequencing further confirmed the methylation increases at the 5’UTR with age observed via 
HRM (Table 2.5), with all individual CpGs showing significant increase in methylation with age 
(Figure 2.11 a & b, positions 2 through 8). The CpG at position 5 (chr7: 147,949,754, mm9) was 
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the most significantly hypermethylated (p=0.007) with the largest beta value of 0.84% increase 
per month of age (Figure 2.11 b).  
 
Figure 2.11 Pyrosequencing data for Cyp2e1. (a) Scatter plot of percent methylation of 
Cytosine-phosphate-Guanine (CpG) and all investigated CpG positions with superimposed line 
plot for each age group connecting the average methylation percentage at each CpG (n=20 per 
CpG, N=80 total). X-axis not drawn to scale. chr 7 = chromosome 7; mm9 = mouse genome 
assembly NCBI37/ build 9, July 2007. (b) Scatter plot of CpG methylation and age of individual 
CpG positions with regression line and statistics under each location. A simple linear regression 
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was performed on all 20 data points for each CpG (n=20) against each age 4, 18, 24, and 32 
months (N=80). Position 1-8: chr7: 147,942,492-147,949,679 - 147,949,684 - 147,949,743 - 
147,949,754 - 147,949,770 - 147,949-791 - 147,949,806, mm9. 
 
 
High Resolution Melt Methylation 
Pyrosequencing Methylation Pearson r p-value 
Pos1 0.5106 0.0013 
Pos2 0.4909 0.0003 
Pos3 0.5122 0.0015 
Pos4 0.4859 0.0002 
Pos5 0.5224 0.0007 
Pos6 0.5185 0.0011 
Pos7 0.3985 8.58E-08 
Pos8 0.4035 6.49E-06 
 
Table 2.5. Pyrosequencing and HRM 5mC correlation. Pearson correlation test result rho (r) and 
p-value of each CpG methylation values investigated by Pyrosequencing and the High-
Resolution Melt (HRM) methylation result of the 5’UTR region of Cyp2e1. The pyrosequencing 
assays confirmed the HRM data with all CpG positions positively correlated with HRM 
methylation. Pos 1-8: Position 1-8 chr7: 147,942,492-147,949,679 - 147,949,684 - 147,949,743 - 




2.4.4. Histone acetylation analysis of Cyp2e1 5’UTR and upstream regulatory region 
We viewed publicly available mouse ChIP-Seq data (GSM1000153, GSM1000140) in 
UCSC genome browser to identify two regions neighboring and/or overlapping the 5’ UTR and 
the upstream regulatory region that showed high histone 3 lysine 9 acetylation (H3K9ac) and 
histone 3 lysine 27 acetylation (H3K27ac) occupancy rates in young mouse liver (Figure 2.1). 
To assay histone acetylation levels in these regions, we used chromatin immunoprecipitation 
coupled to quantitative PCR (ChIP-qPCR). We observed a significant increase in H3K9ac at 
Cyp2e1 intron 1, adjacent to the 5’UTR (Region 1, chr7:147,950,223-147,950,367, mm9) 
(β=0.133, SE=0.06, p=0.044) and at the upstream regulatory region (Region 2, 
chr7:147,942,350-147,942,468, mm9) (β= 0.194, SE=0.08, p=0.041) when regressing ChIP-
qPCR percentage of input on age (Figure 2.12). This corresponds to a 0.133% and 0.194% 
increase in H3K9ac per month of increased age at each site, respectively. However, H3K27ac 




Figure 2.12 Chromatin Immunoprecipitation quantitative polymerase chain reaction (ChIP-qPCR) data. Box plots with regression line 
(blue) of Age-Associated changes to percentage of input occupancy of Histone 3 Lysine 9 acetylation (H3K9ac) (n=20 per region), 
Histone 3 Lysine 27 acetylation (H3K27ac) (n=20 per region) at Cyp2e1 intron 1 (Region1, chr7:147,950,223-147,950,367, mm9) and 
promoter (Region 2, chr7:147,942,350-147,942,468, mm9). IgG percentage of input shows a low background noise signal for each of 
the sample’s age groups (n=20 per region). Data represent median (middle hinge), 25% (lower hinge) and 75% (upper hinge) quantile. 
Data points beyond upper or lower 1.5 * Inter Quantile Range are represented as individual black dots.
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 2.4.5. CYP2E1 pharmacokinetics, chronological age, and epigenetics 
As shown above, 5mC and H3K9ac levels at Cyp2e1 changed with age in tandem with 
reduced gene and protein expression in our sample. To determine if these effects impacted 
CYP2E1 metabolic activity, we assayed metabolism of the CYP2E1-specific probe drug 
chlorzoxazone (CZ) in microsome extracts from the same livers. The average microsome yield 
was 1.07% w/w [0.55-1.69], which was within expected range (Knights et al. 2016). Linearity of 
the HPLC assays of R2 ≥0.999 were established for 2.34-1200 µM CZ and 0.46-240 µM 6-OH-
CZ (Figure 2.2 and 2.3). Linearity of 6-OH-CZ formation with reaction time and MLM final 
concentration was established and the final reaction time and MLM concentration was 25 min 
and 1 mg/ml respectively (Figure 2.4 and 2.5). Vmax and Km values were estimated and used to 
calculate intrinsic clearance (CLint) according to Eq2. Initial analyses established that 
chronological age was not significantly associated with CLint of CYP2E1 despite a relatively 
large correlation coefficient (r=0.31, p=0.8). Average Michealis-Menten constants and CLint per 
age group are reported in Table 2.6. Representative Michaelis-Menten curves of each age group 
can be found in Figure 2.13. This result suggests that chronological age is not a robust 
independent predictor of CLint, corroborating prior research (Schmucker et al. 1990; Hunt et al. 













CLint (uL/min/mg protein) 
Mean (+-SD) 
4 626.05 (297.1) 391.44 (196.7) 1.59 (1.51) 
18 602.96 (493.9) 1009.54 (1662.1) 0.59 (0.29) 
24 915.07 (774.7) 377.59 (405.2) 2.42 (1.91) 
32 604.8 (434.3) 732.24 (891.9) 0.82 (0.48) 
 
Table 2.6 Michaelis-Menten Constants per age group. Table reporting mean (+-SD) of the 
pharmacokinetics constants Vmax (pmol/min/mg protein), Km (uM), and CLint (uL/min/mg protein) 




Figure 2.13 Representative Michaelis-Menten curves of each age group. Representative 
Michaelis-Menten curves for (a) 4 months, (b) 18 months, (c) 24 months, and (d) 32 months 
ages. X-axis is parent drug chlorzoxazone concentration (µM). Y-axis is reaction rate 
(pmol/min/mg protein). 
 
We then tested Cyp2e1 epigenetic measures for association with the pharmacokinetic 
variables. All CpGs were associated with CLint (Figure 2.14) and the most significant was with 
CpG at position 8 (chr7: 147,949,806, mm9) (r=-0.29, p=0.0008). Furthermore, H3K9ac levels at 
the upstream regulatory region, but not intron 1, of Cyp2e1 were positively correlated with CLint 




Figure 2.14 Correlation matrix reporting Pearson correlation statistical test result (r). White 
blank cells indicate non-significant association (p>0.05). Refer to Table 2.7 for individual p-
values of each Pearson correlation test of a given pair. Color gradient indicates the direction of 
effect of the association with dark pink representing the strongest positive association of 1 while 
dark gray representing the strongest negative association of -1. Only lower half of the plot is 
shown to prevent redundancy in reporting the results. Age: chronological age, Pos 1-8: Position 
1-8 chr7: 147,942,492-147,949,679 - 147,949,684 - 147,949,743 - 147,949,754 - 147,949,770 - 
147,949-791 - 147,949,806, mm9. Vmax: maximal rate of hydroxylation reaction of 
chlorzoxazone by Cyp2e1, Km: chlorzoxazone concentration at half maximal rate, CL.Int: 
intrinsic clearance, K9: Histone 3 Lysine 9 acetylation in Cyp2e1 intron 1 (chr7:147,950,223-






Table 2.7. Pearson correlation tests p-values for epigenetic and drug metabolism variables. Table reporting Pearson correlation test p-
value for each pair of variables. Age: Chronological age, Pos1-8, Position 1-8: chr7: 147,942,492-147,949,679 - 147,949,684 - 
147,949,743 - 147,949,754 - 147,949,770 - 147,949-791 - 147,949,806, mm9. Vmax: maximal rate of 6-hydroxylation reaction of 
chlorzoxazone by CYP2E1, Km: chlorzoxazone concentration at half maximal rate, CL.Int: intrinsic clearance, K9: Histone 3 Lysine 
9 acetylation in Cyp2e1 intron 1 (chr7:147,950,223-147,950,367, mm9), R2K9 Histone 3 Lysine 9 acetylation in Cyp2e1 promoter 
(chr7:147,942,350-147942468, mm9). 
  Age Pos1 Pos2 Pos3 Pos4 Pos5 Pos6 Pos7 Pos8 K9 R2K9 Vmax Km CL.Int 
Age 0              
Pos1 0.0653 0             
Pos2 0.0818 7.70E-14 0            
Pos3 0.0716 3.97E-14 3.56E-15 0           
Pos4 0.0922 3.79E-12 1.55E-17 9.63E-15 0          
Pos5 0.0705 9.53E-14 2.54E-17 8.87E-19 1.48E-16 0         
Pos6 0.0820 5.76E-11 9.50E-15 1.47E-12 1.25E-15 1.01E-13 0        
Pos7 0.1827 6.65E-08 1.19E-09 1.08E-08 2.97E-10 3.22E-09 2.62E-10 0       
Pos8 0.1568 1.93E-09 5.77E-12 2.06E-10 4.16E-13 3.93E-11 1.94E-12 2.02E-13 0      
K9 0.0808 0.8220 0.9914 0.8680 0.9338 0.9260 0.8881 0.6116 0.6991 0     
R2K9 0.1326 0.3089 0.1978 0.2274 0.1581 0.2115 0.1536 0.0556 0.0843 0.0023 0    
Vmax 0.0315 0.3860 0.5458 0.5289 0.6336 0.5521 0.6367 0.9921 0.8266 0.0250 0.0007 0   
Km 0.3677 0.1023 0.0681 0.0670 0.0491 0.0668 0.0566 0.0255 0.0298 0.0629 5.46E-05 0.0214 0  




In this study, we demonstrated that 5mC and H3K9ac levels change with age at Cyp2e1 
in mouse liver. Furthermore, we showed that these epigenetic changes were significantly 
associated with rates of CYP2E1-mediated drug metabolism in microsome extracts from the 
same livers, while chronological age was not. This finding suggests that epigenetic marks may be 
better predictors of drug metabolism in advanced age than chronological age itself.  
Considering our findings in the context of published work, we found that global 5mC 
levels diminished with increasing age and this effect has been shown before in studies of 
different tissues (Booth and Brunet 2016), including the liver (Wilson et al. 1987). Previous 
reports have also shown reduced global 5hmC in mouse liver with age, as we observed here 
(Tammen et al. 2014). However, recent genome-wide bisulfite sequencing studies in mouse liver 
have shown either a modest excess of hypermethylated sites (Hahn et al. 2017), or no overall 
excess in either direction with age (Gravina et al. 2016). One possible reason for this discrepancy 
is that “genome-wide” approaches such as next-generation sequencing (NGS) are not truly 
representative of the whole genome. For example, NGS approaches typically underrepresent 
repetitive elements because reads in these regions may not align unambiguously to the reference 
genome and so are discarded. This may diminish the influence of repeats on the cumulative 
abundance of methylation in bisulfite sequencing studies. Several classes of repetitive elements 
reportedly lose methylation with age (Cardelli 2018). Therefore, underrepresentation of these 
elements could lead to underestimation of age-related hypomethylation in genome wide NGS 
studies of aging. In our sample, we observed significant hypomethylation of LINE1 elements, 
with an average reduction of 2% per month of age. As LINE1 elements are the dominant repeat 
class in mouse and human, comprising almost 20% of the genome (Mouse Genome Sequencing 
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Consortium et al. 2002), this result could partly explain the discrepancy between global 5mC 
studies and genome-wide bisulfite sequencing studies of aging in liver DNA. 
Considering our locus-specific results, we found that DNA methylation of the Cyp2e1 
5’UTR and upstream regulatory region increased significantly with age, while its gene 
expression declined with age. This supports and extends prior observations in human blood 
studies. For example, Peters et al. (2015) reported a hypermethylated CpG at human CYP2E1 
and decreased gene expression with age. Reduced Cyp2e1 expression was also reported in mouse 
liver tissue aged 28 months compared to 4 months, as detected via RNA sequencing (White et al. 
2015). To date, prior studies of histone PTM changes in the context of aging are limited and we 
are not aware of available published data for the liver. Park et al. (2015) found that histone 
deacetylase inhibitors influenced transcription of cytochrome P450s in cultured hepatocytes, 
suggesting histone acetylation affects expression, but this study did not examine the effect of 
aging nor specific histone acetylation marks. Further work is needed in this area, in particular 
genome-wide analysis of H3K9ac with age, given our findings with respect to H3K9ac in this 
study. 
We observed a significant negative correlation between CLint and Cyp2e1 methylation 
and a significant positive correlation between CLint and Cyp2e1 histone acetylation. The effect 
sizes are substantial, with a maximum correlation of -0.31 for 5mC and 0.49 for H3K9ac, 
suggesting that epigenetics plays a significant role in regulating CYP2E1 hepatic activity. This 
finding may have clinical relevance because CYP2E1 is responsible for the metabolism of 
hepatotoxic substrates such as ethanol, acetaminophen, chlorzoxazone (CZ), pro-carcinogens 
(benzene, chloroform, and N-nitroso-nicotine), and endogenous compounds such as estrogen, 
acetone, and linoleic acid (Lieber 1997; Caro and Cederbaum 2004; Porubsky et al. 2008). 
75 
 
Unlike other cytochrome P450s, human CYP2E1 is not functionally polymorphic and its reported 
variants to date have no clinical or functional effects (Ingelman-Sundberg 2004b; Zanger and 
Schwab 2013). CYP2E1 comprises 5.5–16.5% of the hepatic P450 pool (Zanger and Schwab 
2013) and its substrate profile makes it relevant to older adults due to the detrimental and 
unpredictable ADRs of these substrates. For example, CYP2E1 is inducible at heavy ethanol 
intake which is responsible, along with Alcohol dehydrogenases (ADH), for the majority of 
alcohol-mediated liver toxicity hospitalizations (Caro and Cederbaum 2004). In addition, 
acetaminophen related liver injury is the primary over-the-counter drug-related hospitalization 
(Lee 2017). Acetaminophen hepatotoxicity is mediated by the excessive formation of the toxic 
byproduct N-acetyl-p-benzoquinone imine (NAPQI) and subsequent thiol residue depletion upon 
acetaminophen overdose. CYP2E1 is responsible for NAPQI formation at high acetaminophen 
doses, which highlights its importance in acetaminophen-induced liver damage (French 2013). 
Finally, CZ is a high-risk drug listed on the 2019 American Geriatrics Society Beers criteria for 
potentially inappropriate use in older adults. CZ is a centrally acting skeletal muscle relaxant that 
is strongly recommended to avoid in the elderly due to moderate evidence of poor toleration by 
this population according to these criteria. Taken together, these examples provide evidence for 
clinical significance of the metabolism of drugs that are CYP2E1 substrates.  
A limitation of the study as presented is that we could not manipulate epigenetic levels in 
our post-mortem samples, so the association between epigenetics and drug metabolism is 
correlational, rather than causal. Nevertheless, the use of the probe drug CZ renders the 
association highly specific to the action of CYP2E1. In addition, sex differences in drug 
metabolism have been described, however, our sample was comprised of only male mice. Hence, 
female-specific effects should be investigated in future studies. Age-related changes to 
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pharmacokinetic attributes such as plasma protein binding and hepatic blood flow should be the 
subject of future in vivo investigations that pertain to drugs that are highly protein bound or have 
high hepatic extraction ratio due to the possible changes to these attributes that affect the overall 
disposition of drugs with advanced age (McLachlan and Pont 2012). Looking to the future, this 
work may have clinical applications if extended to human populations. Age-related epigenetic 
changes at human CYP2E1 and other drug metabolizing genes should be studied, and if these 
changes are linked to altered clearance clinically, epigenetic biomarkers of altered drug 
metabolism could be potentially used to guide dosing decisions in older adults. One potential 
issue is that epigenetic modifications vary by cell and tissue type. Therefore, age-related effects 
mapped in the liver will need to be tested for equivalency in peripheral cells or tissues (e.g. 
blood) that are more readily accessible for the purposes of biomarker testing. However, prior 
work by Horvath (2013) and others (Spiers et al. 2016; Zhu et al. 2018) suggests that many age-
related epigenetic changes are consistent across tissues and indeed in this study we demonstrated 
continuity across mouse and human. Future work should investigate genome-wide epigenetic 
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Phase II drug metabolism is poorly studied with advanced age and older adults may 
exhibit significant variability in their expression of phase II enzymes. We hypothesized that age-
related changes to epigenetic regulation of genes involved in phase II drug metabolism may 
contribute to these effects. We examined published epigenome-wide studies of human blood and 
identified the SULT1A1 and UGT1A6 genes as the top loci exhibiting epigenetic changes with 
age. To assess possible functional alterations with age in the liver, we assayed DNA methylation 
(5mC) and histone acetylation (HAc) changes around the mouse homologs Sult1a1 and Ugt1a6 
in liver tissue from mice aged 4-32 months obtained from the National Institute on Aging tissue 
bank. Our liver sample shows significant changes to 5mC and histone 3 lysine 9 acetylation 
(H3K9ac) around Sult1a1 but not at Ugt1a6 with age. Histone 3 lysine 27 acetylation (H3K27ac) 
did not change with age at either locus. Sult1a1 gene expression is positively associated with its 
H3K9ac levels but not with 5mC or chronological age. Our findings indicate that Sult1a1 
expression is under epigenetic influence in normal aging, and that this influence is more 
pronounced for histone acetylation than DNA methylation in this sample. In the future, 






Age-associated changes to hepatic phase II drug metabolism is poorly understood. 
Recently, it has been suggested that epigenetic mechanisms could regulate genes encoding drug 
metabolizing enzymes in older adults (Fisel et al. 2016). Aging is known to be associated with 
extensive changes to epigenetic marks such as 5-methylCytosine (5mC) (Horvath and Raj 2018) 
and, crucially, these changes are not purely stochastic. Several hundred loci in the genome 
exhibit consistent 5mC changes in normal aging and these are known as age-associated 
differentially methylated regions (a-DMRs). Many a-DMRs have functional consequences 
(McClay et al. 2014; Horvath and Raj 2018), leading us to seek out a-DMRs at genes encoding 
drug metabolizing enzymes to determine if they affect regulation of these genes. Previously, we 
showed that a-DMRs at the cytochrome P450 2E1 gene, which encodes a phase I drug 
metabolizing enzyme, showed significant changes with age that were associated with CYP2E1 
function (Kronfol et al. 2020). In the current study, we extend this work to consider genes 
encoding phase II (conjugation) drug metabolizing enzymes. 
Data from epigenome-wide association studies (EWAS) in human blood have shown 
significant changes to 5mC at several phase II genes with age (Heyn et al. 2012; Steegenga et al. 
2014; Reynolds et al. 2014; Peters et al. 2015). However, the degree to which these a-DMRs are 
present and affect gene expression in the liver, the primary site of drug metabolism, is unclear. 
Therefore, the aim of this study is to identify age-related changes to 5mC and histone acetylation 
at genes encoding phase II drug metabolizing enzymes in the liver and test if these epigenetic 
changes are associated with gene expression. This study used liver tissue from mice aged under 
controlled conditions, obtained from the National Institute on Aging tissue bank. 
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We identified two phase II drug metabolism genes, SULT1A1 and UGT1A6, showing 
strong evidence for a-DMRs in human blood studies (Table 3.1). We mapped the associated sites 
in the human genome to their homologous mouse regions and tested for epigenetic changes at 
these regions in mouse liver (Figure 3.1). High-Resolution Melt analysis of bisulfite-converted 
DNA and chromatin immunoprecipitation assays was used to measure 5mC and histone post-
translational modifications respectively (Dozmorov 2015). We observed significant age-related 
epigenetic change at the Sult1a1 gene and confirmed that this change was strongly associated 
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 Exp Exp Meth Meth Meth Meth Both Both Total 
Phase II genes  
SULT1A1 X     X  X 3 
UGT1A6   X    X  2 
UGT2B15        X 1 
GSTT1 X        1 
SULT2B1        X 1 
UGT1A4       X  1 
UGT1A5       X  1 
UGT1A1         0 
SULT1A3         0 
 
Table 3.1. Summary of human EWAS findings for phase II drug metabolism genes. Human ADME genes list from pharmaADME 
(www.pharmaadme.org) was contrasted on the top findings from EWAS and gene expression studies of normal aging in human blood 
DNA. Genes encoding phase II drug metabolizing enzymes that showed significant association in the top findings of these studies is 
marked with an “X”. The total number of studies were a specific gene is a top association in the reported results is shown as a total in 





Figure 3.1 UCSC genome browser tracks showing (a) Mouse Sult1a1 gene location, H3K9ac, 
H3K27ac occupancy, and ORegAnno regulatory elements. ORegAnno track shows identification 
(ID) and transcription factor binding site (orange). Vertical bars highlighted in blue and green 
represent the investigated regions in the High Resolution Melting, and Chromatin 
Immunoprecipitation Quantitative Polymerase Chain Reaction assays respectively (full 
coordinates in Table 3.2), and (b) The homologous genomic region in human showing SULT1A1 
gene location, GeneHancer regulatory elements location and ID, and the identifier of the 








Table 3.2. HRM and ChIP primers and qPCR product sequences. Primers used in the High-Resolution Melt and Chromatin 
Immunoprecipitation Quantitative Polymerase Chain Reaction assays with size of PCR product, genomic coordinates, and assembly 
with CpG count when appropriate.  
Gene 
Primers (5’→ 3’) 
Product size/coordinates/assembly  
Forward Primer Reverse Primer 
 High-Resolution Melt CpG count 
Sult1a1 GGAAGGTGTTTTTGTTTTTATG CTAAAAATATATCTCTCCCAACT 134/chr7:133,820,382-133,820,515/mm9 1 
Ugt1a6 AGTATGAAGGAGATAGTAGAATAT AAAAAACCCATCAAAAAAACAC 206/chr1:90,035,169-90,035,374/mm9 4 
 Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction    
Sult1a1 GGGGAACTCAGACAAACCAC TCCTGCCCAGATACTGGTTC 154/ chr7:133,819,634-133,819,787/mm9  




3.3.1. Mice: Liver tissue samples from 20 male CB6F1 mice (5 subjects in each of four 
age groups 4, 18, 24, and 32 months) were obtained from the National Institute on Aging (NIA) 
tissue bank.  
3.3.2. DNA and RNA extraction: Genomic DNA was extracted using the AllPrep 
DNA/RNA kit (80204, Qiagen, Hilden, Germany) according to manufacturer’s protocol. DNA 
and RNA purity and quantity were measured using a Nanodrop spectrometer (ThermoFisher, 
Waltham, MA).  
3.3.3. Selection of genomic regions of interest: Aging EWAS findings for human blood 
were obtained from published studies (see Dozmorov 2015) and genes encoding drug 
metabolizing enzymes were obtained from the ADME (absorption, distribution, metabolism, and 
excretion) gene list from the pharmaADME consortium (pharmaADME.org), see Table 3.1. A 
complete list of the genomic coordinates of all investigated regions in mouse can be found in 
Table 3.2. Publicly available data from the mouse Encyclopedia of DNA Elements (ENCODE) 
and Ludwig Institute for Cancer Research (LICR) chromatin immunoprecipitation (ChIP) 
sequencing runs on young (8 weeks) male mouse liver tissue were used to identify two regions 
with high levels of histone 3 lysine 9 acetylation (H3K9ac) and histone 3 lysine 27 acetylation 
(H3K27ac) PTMs (GSM1000153, GSM1000140) (Figure 3.1). 
3.3.4. Bisulfite conversion of genomic DNA and High-Resolution Melt (HRM) analysis: 
200ng of liver genomic DNA was treated with sodium bisulfite according to the EZ DNA 
Methylation kit protocol (Zymo Research, Irvine, CA). Mouse genomic DNA of 0, 5, 25, 50, 75, 
and 100% methylation were used as standards (808060M, EpigenDx, Hopkinton, MA). High-
85 
 
Resolution Melt (HRM) assays using MeltDoctor reagents (Applied Biosystems, Foster City, 
CA) on a Quantstudio 3 instrument were used to measure 5mC levels on the promoter and exon 
2 of Sult1a1 and Ugt1a6 (Table 3.2). Samples were amplified by qPCR as follows 10min hold at 
95ºC followed by 45 cycles of: 15sec at 95ºC, 60sec at 60ºC or 55ºC for Sult1a1 or Ugt1a6 
respectively, followed by a melt curve stage. Each reaction included 20ng bisulfite-converted 
DNA and final concentration of 1X MeltDoctor HRM MasterMix (Applied Biosystems), 0.2µM 
forward and 0.2µM reverse primer (Table 3.2). The liver samples and the standards were run in 
triplicate. The Net Temperature Shift values (Newman et al. 2012) of the liver samples were 
interpolated on the standard curve to yield their 5mC percentage. 
 3.3.5. Gene expression analysis by reverse transcription – quantitative PCR (RT-qPCR): 
Gene expression was measured for Sult1a1, Ugt1a6a and Ugt1a6b. We opted to measure the 
gene expression of both isoforms of Ugt1a6 present in mouse liver because they are both 
expressed from the same locus and the 5mC region investigated is shared among them. Hence, 
allowing us to test for whether either isoform is affected by epigenetic changes if present. For 
each sample, 1µg of total liver mRNA was reverse transcribed to cDNA by iScript kit according 
to manufacturer’s protocol (Bio-Rad, Hercules, CA). Aliquots of cDNA were amplified in 
triplicate using final concentration of 1X TaqMan master mix (Applied Biosystems) and 1X 
TaqMan Sult1a1 or Ugt1a6a/b Mouse Gene Expression Assay (Mm01132072_m1, 
Mm01967851_s1, Mm03032310_s1 ThermoFisher). qPCR conditions were as follows 2 min 
hold at 50 ºC then 10min at 95 ºC, followed by 40 cycles of 15 sec at 95ºC and 60 sec at 60ºC. 
Mouse Gapdh endogenous control was also assayed in triplicate (Mm99999915_g1, 
ThermoFisher). Quantification cycles (Cq) were determined using the Relative Quantification 
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application on the ThermoFisher Cloud. Normalized quantification cycles (ΔCq) were obtained 
by subtracting the mean Gapdh Cq from the mean Cq of any of the genes. 
3.3.6. Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction (ChIP-
qPCR): 80 mg of mouse liver per sample was processed using the TruChIP tissue shearing kit 
(520237, Covaris, Woburn, MA). Minced tissue was fixed in 1% formaldehyde for 2 min, 
washed, transferred to a tissueTUBE (Covaris), flash frozen in liquid N2 and pulverized. After 
cell lysis, chromatin was sheared on a Covaris M220 for 8min. 2% of sheared chromatin per IP 
was set aside as input control. ChIP used 5 µL of anti-H3K9ac (39137, Active Motif, Carlsbad, 
CA), or 5µg of anti-H3K27ac (39133, Active Motif), or 5µg of Rabbit IgG isotype control 
(ab171870, Abcam) incubated with 2µg sheared chromatin from each sample overnight (16 
hours) at 4ºC. This mixture was added to Dynabeads Protein G (10004D, ThermoFisher) for 4 
hours at 4ºC before washing and elution of ChIP DNA by heating to 65ºC for 1 hour. After 
elution, samples were treated with RNAse and Proteinase K and DNA was purified using 
QIAquick (28104, Qiagen). 
Each ChIP’ed DNA was amplified in triplicate using PowerUp SYBR Green (Applied 
Biosystems), with 0.2 µM of forward and reverse primers (Table 3.2) as follows: 2min at 50ºC, 
2min at 95ºC followed by 45 cycles of: 15sec at 95ºC, 30sec at 58 ºC or 60ºC for Sult1a1 or 
Ugt1a6 respectively and 1min at 72ºC, followed by melt curve stage. Cq values for each plate 
were downloaded and the mean threshold cycle (Cq) obtained for each sample and normalized to 
the dilution factor (2%=1/50) corrected Cq value (Log2 (50) =5.6438) of the input control to 
obtain ΔCq. The percentage of input was calculated by multiplying 100 by 2
ΔCq. 
3.3.7. Statistics: Linear regression tests were conducted in R version 3.6.1 (www.r-
project.org) with α=0.05. 
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3.4. Results  
 3.4.1. Age-associated changes to Sult1a1 and Ugt1a6 methylation and gene expression 
DNA and RNA extractions from the mouse liver samples were successful with an 
average 260/280 value of 1.94 [1.8-2.1] for DNA and 2.05 [1.94-2.1] for RNA. We tested for 
epigenetic changes in mouse liver DNA using HRM. HRM analysis revealed that 5mC at 
Sult1a1 decreases significantly with age (β=-1.08, 95%CI [-1.8, -0.2], SE=0.38, p=0.011) 
(Figure 3.2 a) but did not change at Ugt1a6 (Figure 3.3 a).  
The observed Sult1a1 promoter 5mC decrease with age translates to a 24% decrease in 
the 32 months group versus 4 months groups. On the other hand, neither of Sult1a1 or Ugt1a6a/b 
gene expression changed in a consistent manner with chronological age in this sample (p>0.05) 
(Figure 3.2 b, Figure 3.3 c/d). 
3.4.2. Histone acetylation analysis of Sult1a1 regulatory region 
To assay histone acetylation levels in these regions, we used chromatin 
immunoprecipitation coupled to quantitative PCR (ChIP-qPCR). We observed a significant 
increase in H3K9ac at Sult1a1 (β= 0.11, 95%CI [0.002,0.22], SE=0.05, p=0.04) (Figure 3.2 c) 
but not at Ugt1a6 when regressing ChIP-qPCR percentage of input on age (Figure 3.3 b). This 
corresponds to a 0.11% increase in H3K9ac per month of increased age at Sult1a1. Furthermore, 





Figure 3.2 Box plots with superimposed regression line (blue) of Age-Associated changes to 
Sult1a1 (a) methylation (n=20), (b) gene expression (n=20), and (c) Histone 3 Lysine 27 and 
Lysine 9 acetylation (H3K27ac and H3K9ac), chromatin Immunoprecipitation quantitative 
polymerase chain reaction (ChIP-qPCR) data (n=20 per target), IgG percentage of input shows a 
low background noise signal for each of the sample’s age groups. Data represent median (middle 
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hinge), 25% (lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower 
1.5 * Inter Quantile Range are represented as individual black dots. (d) linear regression plot of 
percentage of input of H3K9ac and Sult1a1 gene expression.  (n=20 per locus) with reported 






Figure 3.3 (a) Box plot with superimposed regression line (blue) of age-associated changes to 
Ugt1a6 methylation (n=20) (p>0.05). (b) Histone 3 Lysine 27 and Lysine 9 acetylation 
(H3K27ac and H3K9ac), Chromatin Immunoprecipitation quantitative polymerase chain reaction 
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(ChIP-qPCR) data (n=20 per target) (p>0.05), IgG percentage of input shows a low background 
noise signal for each of the sample’s age groups. Data represent median (middle hinge), 25% 
(lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower 1.5 * Inter 
Quantile Range are represented as individual black dots. Box plot with superimposed regression 
line (blue) of age-associated changes to gene expression of (c) Ugt1a6a isoform and (d) Ugt1a6b 





3.4.3. Sult1a1 epigenetics and expression 
As shown above, 5mC and H3K9ac levels at Sult1a1 changed with age. However, 
Sult1a1 gene expression was not associated with chronological age. To determine if epigenetic 
effects impacted Sult1a1 gene expression, we tested the degree of association between 5mC and 
H3K9ac on Sult1a1 with its gene expression. H3K9ac changes on Sult1a1 intron1 are associated 
with its gene expression (β=0.02, 95%CI [0.004,0.04], SE=0.008, p=0.018), explaining 23% of 
the variability of the latter (Adj.R2=0.23, p=0.018) (Figure 3.2 d). However, 5mC at the Sult1a1 
promoter did not associate with its gene expression (p>0.05, data not shown). This result 
suggests that H3K9ac is a more robust independent predictor of gene expression of Sult1a1 than 






This study demonstrates that 5mC and H3K9ac levels change with age at Sult1a1 in 
mouse liver. Furthermore, we showed that H3K9ac was significantly associated with Sult1a1 
gene expression, while chronological age was not. This finding suggests that histone acetylation 
levels may be a better predictor of drug sulfonation by Sult1a1 in advanced age than 
chronological age itself.  
Comparing our findings to published work, we found that Sult1a1 5mC levels diminished 
with increasing age and this direction of effect supports prior observations in human blood 
studies. For example, Reynolds et al. (2014) reported a hypomethylated CpG with age at human 
SULT1A1 (Reynolds et al. 2014) overlapping the homologous mouse region investigated in this 
study. Furthermore, Fu et al. (2012) reported increased Sult1a1 expression in mouse liver tissue 
aged 27 months compared to 3 months, as detected via RT-qPCR (Fu et al. 2012). This suggests 
that increases to Sult1a1 gene expression could occur with age but require more power through 
larger sample sizes to be reliably detectable. On the other hand, age-related changes to 5mC and 
H3K9ac were detectable at Sult1a1 in this study’s sample and H3K9ac is associated with its gene 
expression to a substantial degree of 23%. Prior studies of histone PTM changes in the context of 
aging are limited and we are not aware of existing data for Sult1a1 in the liver. Schroeder et al. 
(2013) found that histone deacetylase inhibitors influenced gene expression of Sult1a1 in specific 
brain regions, prefrontal cortex and nucleus accumbens, of mice suggesting that histone 
acetylation affects expression, but this study did not examine the effect of aging nor changes in 
the liver (Schroeder et al. 2013).  
This finding may have clinical relevance because the SULT1A1 enzyme is involved in 
the sulfonation of drugs including tamoxifen and estrogen replacement therapies (Glatt et al. 
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2001). SULT1A1 comprises the majority, 53%, of the total hepatic sulfotransferase (Riches et al. 
2009) and its substrate profile makes it relevant to older adults because these substrates are 
indicated for the treatment of age-related disease or have detrimental and unpredictable 
toxicities. For example, SULT1A1 activates the prodrug tamoxifen which is essential for its anti-
estrogen activity in the treatment of breast cancer (Brauch et al. 2009). In addition, prior studies 
have implicated genetic sequence variants at SULT1A1 in response to estrogen-replacement 
therapy (Rebbeck et al. 2006; Hildebrandt et al. 2009). Therefore, it is conceivable that age-
related functional epigenetic changes at SULT1A1, as shown here, may similarly affect response 
to estrogen-replacement therapy. This suggests an area of future clinical study in humans. 
A limitation of the study is that we could not directly manipulate epigenetic levels in our 
post-mortem samples, so the relationship between epigenetics and gene expression is 
correlational, not causal. Also, sex differences in metabolism have been reported, but our sample 
was comprised of only male mice. Hence, female-specific effects should be inspected in 
forthcoming studies. Age-related epigenetic changes at human SULT1A1 should be studied, and 
if these changes are connected to altered clearance clinically, epigenetic biomarkers of altered 








3.6. Study Highlights 
What is the current knowledge on the topic?  
The determinants of age-related changes of drug response due to phase II metabolism is poorly 
understood. The study of epigenetic regulation of ADME genes is in its infancy and no reports 
correlate age-related changes to epigenetic regulation of genes controlling phase II metabolism. 
What question did this study address?  
What is the extent of age-related change of DNA methylation and histone acetylation at the 
Sult1a1 and Ugt1a6 genes? What is the extent of association of these epigenetic marks with gene 
expression? 
What does this study add to our knowledge?  
Determine the extent of change to DNA methylation and histone acetylation on sulfonation gene, 
Sult1a1, and its degree of association with its gene expression in advanced age. This study 
reports a lack of change to age-related epigenetic regulation on glucuronidation gene, Ugt1a6, in 
mouse liver. 
How might this change clinical pharmacology or translational science? 
This might stimulate clinical work that determines how we dose older patients based on 
epigenetic levels at genes controlling phase II metabolism to optimize drug response and 






Chapter 4: Cross tissue correlation of Cyp2e1 and Sult1a1 methylation levels in mice 
 
4.1  Abstract 
Epigenetic levels vary by tissue type, yet the degree of variation shared between tissues is 
less established. The relationship between blood methylation and methylation in organs that 
express phase I and II metabolism genes is not well characterized. We hypothesized that blood 
DNA methylation (5mC) levels of genes involved in drug metabolism are correlated with those 
of the liver and the brain. We recently identified the cytochrome P450 2E1 (Cyp2e1) and 
sulfotransferase (Sult1a1) genes as top mouse ADME loci exhibiting epigenetic changes with 
age. To investigate the extent of association between methylation levels of Cyp2e1 and Sult1a1 
in blood and organs that express those genes, we obtained liver, blood, hippocampus, and cortex 
from mice aged 5 months from the Jackson Laboratory. We then assayed 5mC using High-
Resolution Melt assays, around mouse Cyp2e1 and Sult1a1 from these tissues. 5mC of mouse 
livers exhibit significant negative correlation with that of blood at both genes. However, blood 
5mC of neither gene was significantly associated with 5mC in the cortex nor hippocampus brain 
regions. This suggests that epigenetic levels in blood 5mC may inversely reflect those in the liver 
for Cyp2e1 and Sult1a1 genes. This study could serve as the starting point of future in depth 
studies that explicitly looks at blood based 5mC as a proxy to infer the status of methylation on 







 Tissue-specific patterns of DNA methylation are recognized to be highly discordant (Bird 
2002; Zhang et al. 2013; Dmitrijeva et al. 2018). Although significant differences in mean levels 
of 5mC between tissues exist, they should not be used to imply a lack of relationship between 
these marks. Studies have shown that cross-tissue patterns of 5mC can be used to predict a 
singular outcome such as mortality, disease risk, or longevity (Horvath and Raj 2018), indicating 
a mutual underlying process influencing 5mC levels across tissues, however with different 
nuances. We aimed to test this cross-tissue correlation around two genes encoding drug 
metabolizing phase I and II enzymes, Cyp2e1 and Sult1a1 respectively, which have been 
previously shown to be influenced by epigenetic regulation with age (see Chapters 2, 3 and 
Kronfol et al 2020).   
 Changes to hepatic 5mC at Cyp2e1 are associated with changes to gene expression levels 
(Kronfol et al 2020). Furthermore, the regions that we tested were known a-DMRs in human 
blood. However, the degree to which these changes, or lack thereof, in 5mC are present in other 
tissues is unknown. These considerations led us to hypothesize that the variability of hepatic 
5mC could be associated with that of 5mC from whole blood or other tissue that show high 
expression of these genes such as the brain, specifically the cortex and hippocampus. In this 
study, we aimed to test for the degree of association between 5mC levels in the liver, whole 
blood, hippocampus, cortex, and whole brain in young male C57BL6J mice. Through this 
investigation we set out to measure the extent and nature of association between 5mC levels on 




4.3.  Method 
4.3.1. Sample 
All procedures were conducted according to the Institutional Animal Care and Use 
Committee (IACUC) protocol (AD10002047) approved by Virginia Commonwealth University. 
8 male C57BL/6J were purchased from the Jackson Laboratory. Animals were housed in groups 
of 4 and maintained in controlled conditions of 21°C and a 12-h light/dark cycle in microbe free 
environment. Animals were fed standard chow as needed. Animals were healthy and showed no 
signs of aggression or harm. Blood samples were obtained from the submandibular vein prior to 
sacrifice. Animals were sacrificed by decapitation without anesthesia, because this could 
interfere with epigenetic marks. The age of the animals was 5 months at the day of sacrifice. The 
hippocampus and the cortex were dissected from the brain and the remainder was kept as a 
whole and analyzed as “rest of brain”. The hippocampus, cortex, rest of brain, liver, and 100µL 
whole blood mixed with 1% EDTA were collected from each animal and flash frozen in liquid 
N2 and stored in -80°C until day of analysis. 
4.3.2. DNA extraction and bisulfite conversion 
 Genomic DNA (gDNA) was extracted using DNeasy Blood and Tissue kit (69506, 
Qiagen) according to manufacturer’s recommendations. Bisulfite conversion was performed on 
250 ng of gDNA using the EZ DNA methylation kit (D5001, Zymo Research). Single stranded 
DNA quantity and quality were measured by Nanodrop spectrophotometer.   
4.3.3. High-Resolution Melt (HRM) assays 
 HRM assays were performed as previously described for Cyp2e1 and Sult1a1 (Kronfol et 
al). Briefly, 20 ng of bisulfite converted DNA was amplified on Quantstudio 3 using MeltDoctor 
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reagents (Applied Biosystems), 0.2µM forward and 0.2µM reverse primer. For primer and 
product sequence refer to Table 2.2 and Table 3.2. Samples were amplified by qPCR as follows 
10min hold at 95ºC followed by 45 cycles of: 15sec at 95ºC, 60sec at 60ºC or 57ºC for Sult1a1 
or Cyp2e1 respectively, followed by a melt curve stage. The High-Resolution Melt assays 
measured the methylation of 7 and 1 CpG levels for Cyp2e1 and Sult1a1 regions respectively. 
The Net Temperature Shift values (Newman et al. 2012) of the all samples were interpolated on 
the standard curve to yield their 5mC percentage. A standard consisting of 0, 5, 10, 25, 50, 75, 
and 100% methylated mouse genomic DNA was included on each plate (EpigenDx). Both the 
standard and the test samples were run in triplicates.  
4.3.4. Statistics  
















 4.4.1. Cyp2e1 tissue-specific methylation and cross-tissue correlation 
The mean 5-MethylCytosine (5mc) levels of Cyp2e1 in descending order were as follows 
whole blood (93.5%), rest of brain after hippocampus and cortex were removed (66.3%), cortex 
(53.7%), hippocampus (43.5%), and liver (9.3%) (Figure 4.1 a). 5mC typically exerts a 
repressive influence on gene expression; therefore, we should expect the inverse of this pattern 
of descending order for expression in these tissues. This is broadly the case, with Cyp2e1 tissue-
dependent gene expression being highest in liver and lowest in blood, with the brain as an 
intermediate (Figure 4.2 a). Cyp2e1 5mC levels derived from whole blood were negatively 
correlated with those from the liver (r= -0.35, p=0.03) but not with 5mC levels of any of other 
tissues (p>0.05) (Figure 4.1 a). This indicates that an inverse relationship exists between Cyp2e1 
5mC levels in the liver and those of whole blood.  
4.4.2. Sult1a1 tissue-specific methylation and cross-tissue correlation 
The mean 5mC levels of Sult1a1 in descending order were as follows whole blood 
(75%), rest of brain regions (50.3%), liver (39.6%), hippocampus (23.3%), and cortex (22.4%) 
(Figure 4.1 b). This pattern, however, does not resemble that of Sult1a1 tissue-dependent gene 
expression indicating that additional factors regulate tissue-specific gene expression of Sult1a1 
than 5mC alone (Figure 4.2 b). 5mC levels derived from liver Sult1a1 were positively correlated 
with those in the rest of brain (r=0.71, p= 0.03), negatively with blood (r= -0.16, p=0.04), but not 
with the 5mC levels of the other brain regions tested (p>0.05) (Figure 4.1 b). In addition, blood 
5mC levels were negatively correlated with the rest of brain  (r= -0.35, p= 0.02) (Figure 4.1 b). 
Overall, these results indicate an inverse relationship exists between 5mC levels in the liver and 
whole blood for Sult1a1. However, the relationship between blood and liver seems weaker than 
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that of blood and brain. Therefore, blood Sult1a1 5mC measurements are most accurate 
predictors of that of brain regions, excluding the cortex and hippocampus, followed by the liver. 
 
Figure 4.1. Boxplot of DNA methylation percent (DNAm) across the liver, rest of brain, cortex, 
hippocampus, and whole blood arranged in descending order and Correlation matrix reporting 
Pearson correlation statistical test result (r) for either (a) Cyp2e1 (N=40, n=8) or (b) Sult1a1 
(N=40, n=8). White blank cells indicate non-significant association (p>0.05). Refer to Table 4.1 
and 4.2 for individual p-values of each Pearson correlation test of a given pair. Color gradient 
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indicates the direction of effect of the association with dark red representing the strongest 
positive association of 1 while dark blue representing the strongest negative association of -1. 




Figure 4.2. Violin plot showing average expression of either (a) CYP2E1 or (b) SULT1A1 
across liver, whole blood, hippocampus, and cortex. Data obtained and plotted from GTEx 





 Blood Rest of Brain Cortex Hippocampus Liver 
Blood 0     
Rest of Brain 0.1027 0    
Cortex 0.5319 0.9417 0   
Hippocampus 0.1405 0.2067 0.2323 0  
Liver 0.0301 0.1374 0.9634 0.4397 0 
 
Table 4.1 Cyp2e1 P-values for each pair of tissue types 
 
 
 Blood Liver Hippocampus Cortex Rest of Brain 
Blood 0     
Liver 0.0423 0    
Hippocampus 0.2947 0.1223 0   
Cortex 0.9754 0.7008 0.1884 0  
Rest of Brain 0.0258 0.0399 0.0899 0.5042 0 
 
Table 4.2 Sult1a1 P-values for each pair of tissue types 




We previously determined the extent and direction of effect of age-related changes to 
5mC levels at Cyp2e1 in the liver (Kronfol et al 2020). Here, we expanded our understanding of 
tissue-specific variation to 5mC in not only peripheral tissue (whole blood), but also the different 
regions of the brain that have significant expression of Cyp2e1 and Sult1a1. Furthermore, we 
showed that variation in 5mC levels of Cyp2e1 and Sult1a1 in the liver are inversely reflected in 
5mC levels at these genes in whole blood. The size of the inverse correlations was relatively 
large (approximately -0.3). This work confirms a relationship between 5mC levels at these two 
genes in different tissues of the same subject and could pave the way for similar studies in 
humans.   
Considering our findings in terms with previous work, we found equivalent levels of 
5mC as previously reported in mouse liver (Kronfol et al 2020) and blood (Peters et al 2015). In 
addition, for Cyp2e1, our data suggest that only 5mC levels in the liver are correlated with 5mC 
levels in blood. 5mC from other specimens (DNA from buccal or nasal swab, etc) should be 
investigated for correlation with that of different brain regions. For Sult1a1, the data suggest 
blood-derived 5mC is more correlated with 5mC of the brain, excluding the hippocampus and 
the cortex, than with the liver. In addition, tissue-specific gene expression of Sult1a1 might be 
influenced by other factors than 5mC alone. Histone post translational modifications could also 
play a role, but these do not function well as biomarkers because they must be assayed from 
fixed chromatin, not DNA that is more readily available. 
A limitation of our study, in the context of the broader substantive focus of this 
dissertation, is that we did not study how cross-tissue 5mC correlations change with age. Given 
the negative correlation between 5mC levels in blood and liver on Cyp2e1 in young age, we can 
105 
 
predict that any age-related change may also be negatively correlated. Such that if we see age-
related hypermethylation in the liver, we will see hypomethylation in blood. In addition, we 
typically see regions that are constitutively methylated at young age, like blood 5mC in this case, 
become hypomethylated due to epigenetic drift and attrition with age (Issa 2014; Jones et al. 
2015; Zhu et al. 2018). Nonetheless, this study explicitly looked at the lower end of the mouse 
adulthood of an age of 5 months and the data should serve as a reference for future investigations 
of the relative baseline levels of 5mC in the brain, liver, and blood at older ages. 
Limitations of this study include the exclusion of female mice. However, we anticipate 
that this should be included in future, larger studies. Studies intended to examine a wider range 
of the adult life of mice could be performed, or similar studies could be attempted for humans if 
DNA from multiple tissues (e.g. blood, liver) can be obtained from the same individuals. This 
may be possible from some biobanks. Finally, more work is needed to establish whether the 
extent of the relationship between 5mC on drug metabolism genes in blood and liver can be 
clinically useful as a proxy to guide drug dosing decisions. 
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Chapter 5: Method optimization of Reduced Representation Bisulfite Sequencing (RRBS) 




DNA methylation is the most widely studied epigenetic mark to date. Several methods 
have been proposed to aid the accurate measurement of DNA methylation in the context of 
Cytosine-Phosphate-Guanine (CpG) positions in mammalian genomes. However, few have been 
adopted and implemented for different applications as much as reduced representation bisulfite 
sequencing (RRBS). RRBS has been widely used to optimize DNA methylation detection from 
tissues and cells, yet few methodologies expand the sequencing library preparation portion of 
RRBS. We proposed to augment the RRBS protocol using a commercially available Adaptase 
library technology to create optimized library complexity intended for the detection of CpG 
DNA methylation from mouse liver tissue belonging to young (4 months) and old ages (32 
months). We report that this optimization produced high yields of RRBS libraries with consistent 
DNA fragment distributions between both ages and high proportions of shared number and 
positions of Cytosines assayed per age. We first start with the same procedure of column-based 
DNA extraction that is then enzymatically cut by Msp I, a methylation indifferent restriction 
enzyme. However, we perform DNA fragment size-selection of 100-220 bp followed by bisulfite 




5.2.  Introduction 
 
Reduced Representation Bisulfite Sequencing (RRBS) is a robust method for detecting 
methylation and has been carried out by researchers for more than a decade and cited over 800 
times (Meissner et al. 2005). We propose to optimize the current technique by coupling it with 
the Adaptase advanced library amplification technology for the detection of CpG DNA 
methylation obtained from mouse liver tissue. This method optimization effort will serve as the 
primary assay for a larger aging epigenome-wide association study by our group. We focus on 
DNA methylation because it is the best-characterized epigenetic mark, both overall and in the 
context of aging. 
Our method of choice, RRBS, is robust and cost-effective, providing good coverage of 
CpGs in genes and regulatory regions (Gu et al. 2011). RRBS is not new, however, its 
application to aging and drug metabolism is highly innovative, because future findings may shed 
light on mechanisms of aging and open new avenues of research into novel biomarker strategies. 
We propose to use RRBS specifically for several reasons. Genome-wide DNA methylation 
analysis is typically carried out using microarrays or next generation sequencing (NGS) (Rakyan 
et al. 2011). Methylation arrays for humans are excellent, with the Illumina Infinium capable of 
measuring 5mC at ~850,000 loci. However, there are no equivalent arrays for mice. The best 
option we are aware of is the Mouse CpG Island Microarray from Agilent, which can assay 
~90,000 loci, much less than the human arrays. However, the extent of genome-wide coverage 
offered by arrays of any kind is poor relative to Next Generation Sequencing (NGS). The gold-
standard for genome-wide DNA methylation analysis is whole genome bisulfite sequencing 
(WGBS) (Lister et al. 2009; Rakyan et al. 2011). Here, the entire genome is subjected to bisulfite 
treatment and sequenced to high depth of coverage, providing single base resolution of 
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methylation. This makes it very attractive, but it is still too costly for the large numbers of 
samples required for association studies. RRBS, one the other hand, is an excellent compromise. 
Using enzymatic digestion at CpG sites followed by fragment size selection, the sequencing 
libraries are enriched for regions of the genome with high CpG density, which are often 
important regulatory regions. By trading full genome-wide coverage for high-resolution at these 
important loci, RRBS requires just ~20 million reads per sample, thereby enabling sufficient 
numbers to be assayed for an association study (Gu et al. 2011).  
We focused on 5-methylCytosine (5mC) instead of other DNA modifications for various 
reasons. Although other DNA modifications have been discovered, 5-hydroxymethylcytosine 
(5hmC) (Kriaucionis and Heintz 2009; Pastor et al. 2011) or 5-formylcytosine (5fC) (Bachman et 
al. 2015), the role of 5mC in cell differentiation and regulation is the best-characterized, meaning 
that 5mC results are more readily interpretable. Furthermore, the bisulfite sequencing approach 
(RRBS) (Meissner et al. 2005; Gu et al. 2011) that we intend to optimize works by converting 
unmethylated cytosines to uracils via sodium bisulfite treatment (which then convert to thymines 
in PCR) (Frommer et al. 1992).  
Previous epigenome-wide association studies of liver tissue have used RRBS methods 
that prepare sequencing libraries in a conventional way (Hahn et al. 2017; Stubbs et al. 2017). 
However, a recent systematic evaluation of library preparation methods by Li et al ((Zhou et al. 
2019) shows that the new Adaptase technology outperforms traditional library techniques. The 
authors conclude that libraries prepared by Adaptase achieve the highest proportion of CpGs 
assayed, most effective sequencing coverage, and lowest proportion of low-quality reads. No 
published reports utilize this new technology for liver RRBS. Therefore, we wanted to 
implement the Adaptase method in the RRBS protocol for liver DNA. We took this novel 
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method to see how it performs in test samples and obtain quality control information. Briefly, the 
Adaptase enzyme maximizes the recovery of low concentrations of single stranded DNA by 
ubiquitous ligation and priming by universal tags. This ensures successful subsequent 
amplification of all DNA fragments. Thus, preserving DNA information and library complexity.  
We subjected 600 ng of genomic DNA from mouse liver to DNA methylation analysis by 
RRBS using the commercially available Adaptase technology in the ACCEL NGS Methyl-Seq 
Kit (Swift Bioscience). This involved Msp I digestion of DNA, size-selection, bisulfite 
conversion, simultaneous tailing and ligation by Adaptase of all single stranded DNA fragments, 
3’extension, bottom strand ligation, and finally unique sequencing adapter ligation through PCR 
amplification to produce the final sequencing library (Figure 5.1). Library size distribution and 
integrity was validated using the high-sensitivity DNA chip on an Agilent BioAnalyzer. 
Multiplexed pair end 150bp sequencing was carried out on an Illumina HiSeq 4000 at the 
GeneWiz service provider sequencing facilities. We carried out NGS on 4 test samples. We 
aimed to exceed the recommended 20-25 million reads needed to obtain enough coverage depth 










 Genomic DNA was obtained from 20 mg liver tissue of 4 months old sample and a 32 
months old sample using the AllPrep DNA/RNA kit (Qiagen). DNA quality and quantity were 
measured on Nanodrop spectrophotometer (ThermoFisher) and Qubit 4.0 (ThermoFisher) 
respectively. 
5.3.2. Reduced Representation Bisulfite Sequencing (RRBS) 
RRBS libraries were prepared as previously described (Gu et al. 2011) with slight 
modifications. 600 ng genomic DNA was cut enzymatically by Msp I (R0106T, New England 
Biolabs, Ipswich, MA) overnight (16hrs) at 37 °C, then purified the next day by QIAquick PCR 
purification kit (Qiagen). The purified Msp I digested DNA was run on a 2% ethidium bromide 
agarose gel adjacent to a paired lane of genomic DNA of the same sample to check for 
successful Msp I digest. Unsuccessful digests were repeated. The sample was size selected for 
fragments between 100-220 base pair (bp) long using the 2% ethidium-free agarose gel cassette 
(CEF2010, Sage Science, Beverly, MA) on a Pippin Prep machine. The Pippin Prep protocol was 
set to the “Range” collection mode and reference lane 3 was used for the provided marker E. 
Samples were collected from the elution module using 40µL of provided electrophoresis buffer. 
The size selected Msp I digested DNA was bisulfite converted by the EZ DNA methylation kit 
(D5001, Zymo Research, Irvine, CA) according to manufacturer’s recommendation. Briefly, 
samples were incubated at 37 °C for 15 min followed by overnight (16hrs) incubation with 
100µL of provided CT conversion reagent at 50 °C to allow the deamination process of 
unmethylated cytosines into uracils to occur. Samples were eluted in a final 10µL elution buffer. 
2 µL was used to measure the concentration of the samples using the ssDNA Qubit assay 
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(Q10212, ThermoFisher). Samples with concentration below detection range were repeated. 
Finally, about 3 ng of Msp I digested, size-selected, and bisulfite converted DNA was used as 
input for the ACCEL-NGS Methyl-Seq DNA Library kit (30024, Swift Bioscience) to create the 
RRBS libraries. 
Briefly, 8µL of sample was mixed with provided low EDTA TE buffer q.s 15µL and 
incubated at 95 °C for 2min and then placed on ice, spun down and added to 25µL of Adaptase 
reaction mixture. The Adaptase reaction mixture components are 11.5µL of low EDTA TE, 4 µL 
each of provided Buffer G1 and Reagent G2, 2.5 µL Reagent G3, and 1 µL each of Enzyme G4, 
5, and 6. The mixture was incubated at 37 °C for 15 min, then at 95 °C for 2 min. The samples 
were kept on ice followed by the addition of 44 µL of Extension Reaction mixture containing the 
following, 2 µL Reagent Y1, 42 µL Enzyme Y2. The samples were mixed and incubated at 98°C 
for 1 min, followed by 62 °C for 2 min and 65 °C for 5 min and a 4°C hold. The samples were 
then cleaned up from reaction components using 134 µL of SpriSelect beads (Beckman-Coulter). 
The samples were eluted in 15µL low EDTA TE and added to 15µL of the Ligation mixture. The 
Ligation mixture contained 3 µL Buffer B1, 10 µL Reagent B2, 2 µL Enzyme B3. The samples 
were incubated at 25 °C for 15min. The samples were cleaned up from reaction components with 
42 µL beads. The samples were eluted in 20 µL low EDTA TE buffer. 5 µL of unique index 
from Methyl-Seq Set A indexing kit was used per sample (36024, Swift Bioscience). Each of the 
young and old sample was run twice with different indices. 25 µL of PCR reaction mixture was 
added that contained the following 10 µL low EDTA TE buffer, 10 µL Buffer R1, 4 µL Reagent 
R2, 1 µL Enzyme R3 and allowed to amplify on Proflex thermal cycler (Applied Biosystems). 
PCR conditions were as follows 98 °C for 30 sec followed by 10 cycles of 98°C for 10sec, 60°C 
for 30sec, 68°C for 60sec, and a final hold at 4°C. PCR reaction was cleaned up twice with 50µL 
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of SpriSelect beads following manufacturer’s recommendation for libraries intended for 
sequencing on patterned flow cells such as HiSeq4000. Final libraries were eluted in 22µL low 
EDTA TE and 1µL was used to measure concentration using the DS DNA Qubit assay 
(ThermoFisher). 1µL was used to trace the size-distribution and average library size on the HS 
DNA chip on Agilent 2100 Bioanalyzer. Libraries were sequenced pair ended 150 bp on 
Illumina HiSeq4000 using 5% Phi-X spike-in (as positive control for successful sequencing run) 
by GeneWiz service provider. Each RRBS sample yielded a single Fastq file. The reverse reads 
were discarded.  
5.3.3. Data processing  
Sequencing reads (FASTQ files) were mapped to the mouse genome (mm10) and 
methylation calls are made using Bismark (Krueger and Andrews 2011), which is based on Bowtie 
(Langmead and Salzberg 2012). Bismark yielded for each RRBS sample a quality control file and 
one coverage file per sample with CpG position and methylation information, expressed as 




5.4  Results 
5.4.1. DNA extraction, MspI digestion, and fragment isolation 
DNA extraction from the mouse liver samples was successful with mean DNA 
concentration of 120 ng/µL with an average 260/280 value of 2.0 [1.93-2.06]. 600 ng of genomic 
DNA was enzymatically cut with MspI and was size selected for fragment between 100-220 bp, 
which gave the highest resulting yield of 0.5-1% w/w, which was within expected range 
(Meissner et al. 2005).  
5.4.2. RRBS library preparation and Quality control  
3ng was used as input for library preparation. Library amplification was successful with a 
final library concentration of 12.9 ng/µL for an average of 258 ng per sample. Average library 
size and molarity was 301 bp and 63.6 nMol respectively. Our RRBS library distribution shows a 
unique pattern of three distinct peaks similar to those previously reported. Three unique peaks at 
259, 282, and 316 bp were present in the BioAnalyzer trace of the RRBS libraries (Figure 5.2).  
Each peak represents high abundance of fragments of similar fragment sizes. This peak profile is 







Figure 5.2. Representative RRBS library trace. Showing peaks distinct to RRBS libraries at 259, 
282, 316 bp. X-axis is Arbitrary fluorescence units [FU], y-axis is fragment size in base pair 
[bp]. A peak at 35 and 10380 bp indicate the lower and upper ladder marks for the High 






Age (months) Sample ID Index Index sequence 
4 4-11 replicate 1 I4 TGACCA(AT) 
4 4-11 replicate 2 I2 CGATGT(AT) 
32 32-15 replicate 1 I5 ACAGTG(AT) 
32 32-15 replicate 2 I16 CCGTCC(CG) 
 
Table 5.1. Summary table reporting chronological age (months) and ID of each sample, 
index and index sequence used. 
 
Age (months) Total number of reads 




4m rep1 37,014,015 19,576,596 0.549 
4m rep2 54,032,672 27,520,231 0.509 
32m rep1 57,122,708 28,007,798 0.490 
32m rep2 41,196,659 16,898,265 0.410 
 
Table 5.2. Summary table reporting average total number of reads and total number of 
Unique Alignments per age (months) 
Age (months) 
Number of Cytosines 
assayed post-QC 
Cytosines in common 
across 2 replicates 
Proportion in common 
across 2 replicates 
4m rep1 1,048,263 
1,029,626 0.982 
4m rep2 1,171,890 
32m rep1 1,176,430 
1,026,686 0.978 
32m rep2 1,050,249 
 
Table 5.3. Summary table reporting number of unique cytosines captured per replicate 
after quality control (n reads per cytosine: 10 < C >300) 
 
5.4.3. Next Generation Sequencing (NGS) data 
Bismark was run according to default settings for RRBS fastq files (Krueger and 
Andrews 2011). Reference mouse genome used was mm10. Bismark output included a summary 
file and a methylation coverage file per sample. Total sequences analyzed for each replicate of 
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the 4 and 32 months samples respectively are shown in Table 5.2. Reads with unique alignments 
per sample ranged from 16.9M to 28M per sample/replicate (Table 5.2). The percentage of 
unique alignment to total sequence analyzed was approximately 50% for 3 of the 4 samples. 
These values improve upon previously reported results from traditional RRBS (Chatterjee et al. 
2012). while replicate 2 of the 32 month sample was somewhat lower at 41% and this made the 
average percentage alignment for the 32 month samples somewhat lower (Figure 5.3 a). Quality 
control (QC) of cytosine position coverage was set at the levels used by Stubbs et al. whereby 
sites with 10 or fewer reads and those with 300 or more reads are discarded. Despite replicate 2 
of the 32 month sample having least aligned reads (Table 5.2), the number of Cytosine positions 
with good data, i.e. 1,050,249 after QC, was still slightly more than for replicate 1 of the 4 month 
sample (Table 5.3). Overall, despite the number of uniquely aligned read numbers differing by a 
factor of 1.6 across the samples, the number of Cytosine positions passing QC was remarkably 
similar. Most importantly, replicates returned high quality quantitative information for almost the 
same sets of approximately 1 million Cytosine positions (98% the same) despite there being 
approximately 20 million CpGs in the mouse genome. This showed that the replicates were 
highly consistent in the regions of the genome they captured. 
The percentage 5mC (in CpG context) was 37.25 and 33.85 % for the 4 and 32 months 
respectively (Figure 5.3 b). The percentage of non CpG methylation detected was about less 
than 1.5 % for both ages. This data suggests that the sequencing of the RRBS libraries was 
successful with equivalent numbers of total cytosine detected for both ages. However, a clear 
decrease in the CpG methylation calls was present in the 32 months (old) age compared to the 4 
months (young) age. This effect direction mirrors that observed using ELISA global assay in 




Figure 5.3. Bar plot of data from Bismark quality report showing (a) Percentage of total and 










 We previously initiated a set of studies investigating liver specific methylation changes 
with age at candidate genes involved in phase I and II metabolism. Our studies were based on a 
gene selection approach identified from large epigenome-wide association studies in human 
blood. Indeed, these studies demonstrated, to the best of our knowledge, the first evidence of the 
influence of age-related epigenetics changes on the pharmacokinetics of drug metabolizing 
enzymes. However, several other genes from these human studies showed varying degree of 
evidence of change with age. An estimated one third of all genes involved in ADME processes 
show various levels of association with age (Dozmorov 2015). Therefore, optimization of a 
highly reproducible method for the genome-wide quantitation of epigenetic marks at regions of 
regulatory importance was warranted. We demonstrated in this study the feasibility of using 
RRBS to quantify 5mC from mouse liver DNA of old and young age that can be leveraged to 
larger epigenome-wide aging studies. This is an ongoing effort in our lab, where we will attempt 
to elucidate the degree of age-related variation of 5mC on genes controlling the attributes of 
mouse hepatic metabolism on a genome-wide basis.  
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Chapter 6: Overall Conclusions and Future Directions 
Through this work we have demonstrated a novel approach for answering an overarching 
question of what additional determinants of biological variability are affecting drug metabolism 
in advanced age. Our hypothesis that epigenetic mechanisms such as DNA methylation and 
histone modifications influence drug metabolism with age was warranted in order to set the stage 
for new technologies to overcome the limitations of current tools used in the clinic that guide 
drug dosing decisions in the older adult population. We aimed to elucidate the nature of the 
relationship between epigenetic dysregulation and the function of drug metabolizing enzymes in 
advanced age. In fact, we were able to define the continuity of the relationship from DNA to 
function in a unique set of experiments that, to the best of our knowledge, have not been pursued 
before. In addition, this work described the influence of epigenetics on genes encoding both 
phase I and II metabolizing enzymes. We show that both phases are under the influence of age-
related epigenetic change with varying degrees and through shared and distinctive mechanisms. 
For phase I, we showed that the Cyp2e1 gene is under the influence of age-related changes to 
5mC and histone acetylation (H3K9ac). The degree of effect on the downstream function of 
CYP2E1 is substantial for both epigenetic marks. On the other hand, while 5mC and H3K9ac 
levels at the Sult1a1 phase II metabolism gene changed with age, only H3K9ac was shown to 
influence expression.  
Epigenetic modifications have demonstrated clinical usefulness through successful 
examples, such as the use of DNA methylation as a clinical biomarker to guide drug selection. 
For example, MGMT methylation status is now being used clinically to guide treatment selection 
for glioma multiforme patients. We believe DNA methylation could be utilized in the clinic as a 
clinical biomarker to guide drug dosing decisions for older adults. Although H3K9ac was a 
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better predictor of function for both Cyp2e1 and Sult1a1, it is difficult to conceive of histone 
modifications being used as clinical biomarkers using the methods we employed here (chromatin 
immunoprecipitation). Alternative, novel methods that are more rapid and robust will be needed 
before histone acetylation can see widespread use as a clinical biomarker.  
DNA methylation is easy to obtain from peripheral tissue such as blood. Here, we 
demonstrated correlations between levels of 5mC in the liver for Cyp2e1 and Sult1a1 and those 
in whole blood. These relationships suggest that blood-based biomarkers may reflect hepatic 
5mC levels and these may be useful to guide drug dosing in the future. However, significant 
additional work in humans will be necessary to demonstrate the feasibility of this innovation.  
The work as presented here serves as a first step towards future research aimed at 
evaluating the utility of epigenetics in the clinic. Our group is in the process of pursuing a larger 
ageing study that examines the degree of genome-wide 5mC change with age in a mouse model. 
We believe that similar efforts might be underway and along with ours will serve the aging 
community to alleviate one of the major problems currently facing the older adult population, 
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